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Abstract
Scleritis is a highly symptomatic inflammatory disease of the sclera. We conducted a
retrospective study to identify demographic factors and comorbidities associated with the
resolution of scleritis, to compare patient outcomes for different treatments for scleritis,
and to compare treatment utilization by the different medical specialties that manage
scleritis. The medical records of all patients with a CPT code for scleritis seen at a
tertiary care center from January 1, 2013 to January 1, 2020 were reviewed. Data was
collected on demographic factors, comorbidities, and treatment. The primary outcome
measures were time until resolution of disease, defined as quiescence of inflammation on
two or more sequential visits, and time until resolution on steroid-sparing therapy,
defined as being on 10 milligrams or less of prednisone without a recurrence of
inflammation on two sequential visits. The study was approved by the Yale School of
Medicine Institutional Review Board (IRB). We identified 256 patients (302 eyes) with
scleritis, including 232 patients (90.6%) with diffuse anterior scleritis, 10 patients (3.9%)
with nodular anterior scleritis, two patients (0.8%) with necrotizing scleritis with
inflammation, and three patients (1.2%) with necrotizing scleritis without inflammation
(scleromalacia perforans). The most commonly used therapies were topical steroids
(44.9%), systemic NSAIDs (34%), and systemic steroids (34%). Non-corticosteroid
immunomodulatory therapies (IMTs) were required in 39.5% of patients, most commonly
methotrexate (17.2%) and TNF-⍺ inhibitors (9.1%). Scleritis was associated with a
systemic autoimmune disease in 90 patients (35.2%). These patients were more likely to
receive systemic corticosteroids and non-corticosteroid IMTs (p<0.05). Patients with an
ophthalmologist involved in their care were more likely to receive acute treatment

(p<0.05) and were more likely to receive systemic NSAIDs (p<0.05). Resolution was
achieved within 3 months in 45.6% of patients and within 6 months in 57.6% of patients.
Steroid sparing resolution was achieved within 3 months in 35.9% of patients and within
6 months in 48.9% of patients. In a Cox proportionate hazards model, NSAID use
(p<0.05, OR 2.145, 95% CI [1.200, 3.832]), Hispanic race (p<0.05, OR 2.664, 95% CI
[1.036, 6.851]), lupus erythematosus (p<0.005, OR 6.175, 95% CI [1.774, 21.489]), and
bilateral scleritis (p<0.05, OR 0.437, 95% CI [0.196, 0.972]) were significantly
associated with the resolution of scleritis. TNF-⍺ inhibitors were associated with
resolution only at the 90% confidence level (p<0.1, OR 2.210, 90% CI [1.100, 4.440]).
TNF-⍺ inhibitors (p<0.05, OR 3.346, 95% [1.277, 8.763]), biologic therapy (including
TNF-⍺ inhibitors, when compared against antimetabolites, p<0.01, OR 2.506, 95% CI
[1.406, 7.634],) lupus erythematosus (p<0.05), OR 5.251, 95% CI [1.478, 18.659]),
African American race (p<0.05, OR 0.467, 95% CI [0.224, 0.973], and NSAIDs
(p<0.005), OR 2.558, 95% CI [1.383, 4.729]) were significantly associated with steroid
sparing resolution. In conclusion, patient characteristics including a lupus diagnosis and
Hispanic race were associated with resolution and steroid sparing resolution, as were
treatments including systemic NSAIDs and TNF-⍺ inhibitors. There were differences in
medication utilization among specialty types, and patients with scleritis may benefit from
ophthalmologic consultation. Future prospective studies will further elucidate the
relationship between these factors and patient outcomes.
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Introduction
Background and Objectives
Scleritis is a relatively uncommon, highly symptomatic inflammatory disease of the
sclera. It is typically divided into diffuse anterior, nodular anterior, necrotizing, and
posterior subtypes (1). In most cases the disease is restricted to the eye, however in an
estimated 20-50% of patients, it may be associated with a systemic inflammatory illness
(2- 6). Rheumatoid arthritis is particularly prevalent among patients with scleritis, but
granulomatosis with polyangiitis, relapsing polychondritis, systemic lupus erythematosus,
inflammatory bowel disease, seronegative polyarthropathies, Sjogren’s syndrome, and
polyarteritis nodosa are also associated with scleritis (2-3, 6-7, 9). In rare cases it may be
associated with localized infection, such as herpes simplex, varicella zoster, bacterial, or
fungal infections, or with systemic infectious etiologies, such as syphilis or tuberculosis
(10-11). Scleritis can be refractory to treatment and can cause vision-threatening
complications including severe thinning of the sclera and globe perforation.
Numerous treatment options are available for acute scleritis. Initial therapy often
includes oral NSAIDs (12-13). A variety of NSAIDs have been used for scleritis (e.g.
indomethacin, ibuprofen, naproxen, flurbiprofen). When patients are refractory to
NSAIDs, corticosteroids can be administered topically, systemically, or via local subtenon injections. If the response is not adequate then therapy can be escalated to include
immunomodulatory agents including calcineurin inhibitors (e.g. cyclosporine,
tacrolimus), antimetabolites (e.g. methotrexate, azathioprine, mycophenolate), alkylating
agents (e.g. cyclophosphamide, chlorambucil), and biologics (e.g. infliximab,
adalimumab, certolizumab, rituximab) (14-15). The evidence supporting these treatments
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is variable, ranging from randomized clinical trials (e.g. for rituximab) to sporadic case
reports (e.g. for adalimumab and certolizumab) (16-18).
There is little data comparing the efficacy of these treatments, and treatment
generally relies on the experience of the rheumatologists and ophthalmologists caring for
these patients. In particular, there is limited data on the newer biologic class of agents
which are being increasingly used by rheumatologists and ophthalmologists to manage
scleritis. In addition, there is limited data on the epidemiology of scleritis and its
associated comorbidities.
We hypothesize that different treatment modalities will be associated with
different times to resolution of symptoms and times to steroid-sparing resolution. We also
hypothesize that we will be able to identify differences in outcomes among patients with
different comorbidities and demographic factors, and that there will be differences in
treatment utilization among different medical specialties that manage scleritis. As such,
the objectives of our study are to use retroactive analysis to accomplish the following:
1). To compare time to resolution of symptoms and time to steroid-sparing
resolution among those that have received different therapies for scleritis in our patient
population.
2). To identify demographic factors and comorbidities that may influence
treatment success.
3). To compare treatment utilization by the different specialties that manage
scleritis, including ophthalmology, rheumatology, emergency medicine, and primary
care.
Literature Review
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Numerous patient factors have been noted to affect treatment outcomes in patients
with scleritis. For example, patients that have scleritis in association with a systemic
disease were more likely to require more aggressive treatment (8, 19). Another series
found patients with systemic disease were also significantly more likely to have visual
decline than patients with idiopathic scleritis (8). Lavric et al. noted that Crohn’s disease
was associated with an increased risk of recurrence in patients with posterior scleritis
(20). Another study found that patients with relapsing polychondritis were more likely
than those with idiopathic scleritis to have necrotizing scleritis, recurrence, and decreased
vision when compared to patients with other autoimmune diseases (21). In one study,
smokers were found to take an average of one month longer to respond to therapy than
non-smokers (22). Other factors, such as female gender, have been associated with
increased rates of scleritis but have not been associated with disease severity or treatment
response.
Scleritis is a fairly uncommon disorder, therefore there is limited large series or
randomized clinical trials characterizing the types of scleritis or the efficacy of different
treatment. A number of therapies are used in the management of scleritis including oral
NSAIDs, topical steroids, topical NSAIDs in select cases, locally injected corticosteroids,
systemic corticosteroids, and non- corticosteroid immunomodulatory therapies (IMTs)
(14-15). Tappenier et al. proposed a stepwise approach to management that started with
systemic NSAIDs, followed by systemic corticosteroids, and then non-corticosteroid
systemic immunomodulatory agents (12). They did not recommend the use of topical
corticosteroids as monotherapy. Foster et al. proposed a similar “step-ladder” approach
for ocular inflammation, also starting with NSAIDs, followed by systemic
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corticosteroids, with non-corticosteroid agents added 2-3 months later to decrease
patients’ exposure to corticosteroids and their risk of systemic side effects (13).
A small number of studies have characterized the utilization of the types of
treatments being used for scleritis. For example, in another retrospective study of 128
patients with episcleritis and scleritis, including 93 with scleritis 28.9% were treated with
topical corticosteroids alone, 1.1% were treated with NSAIDs, 58.1% received oral
corticosteroids, and 15% were treated with a non-corticosteroid immunosuppressive drug
(23). The prevalence of usage of specific immunosuppressive drugs was not reported in
this study.
Other studies have included some data on the use of specific immunosuppressive
drugs. For example, in one retrospective study of 134 scleritis patients, of whom 69 had
treatment information available, 30% of the patients with scleritis required oral
nonsteroidal anti-inflammatory drugs, 31.9% required oral corticosteroids, and 26.1%
required non-corticosteroid immunosuppressive drugs (8). The authors reported that
cyclophosphamide was the most commonly used agent. In a study of 123 Japanese
patients with scleritis, 35% of patients received topical corticosteroids, 15.4% received an
injection of triamcinolone acetonide, 23.6% received oral NSAIDs, and 52.8% received
systemic immunosuppressive medications. The most common of these was systemic
corticosteroids in 45.5% of patients, followed by methotrexate in 11.4% of patients (2).
Notably, neither of these studies included patients on biologic therapies and they did not
attempt to assess the efficacy of the treatments used.
Lavric et al. did attempt to assess the efficacy of agents (20). In their study of 114
patients with posterior scleritis 48.2% received topical steroids, 38.6% received oral
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systemic steroids, 8.8% received intravenous steroids, 4% received periocular steroid
injections, 34.2% received systemic NSAIDs, and 32.5% received systemic noncorticosteroid immunosuppressive medications. The most commonly used noncorticosteroid immunosuppressive medication was azathioprine (17.5% of patients),
followed by mycophenolate (7.0% of patients). The authors assessment of mycophenolate
found that patients on mycophenolate had longer resolution times. Of note, the authors
did not assess the efficacy of biologics because only a small number (less than 5%) of
patients received any biologic agent.
Systemic NSAIDs and systemic steroids are the mainstay of treatment for acute
scleritis. Multiple studies have demonstrated their efficacy. Watson et al. demonstrated
the efficacy of NSAIDs and corticosteroids and recommended indomethacin as a first line
treatment (1). In 1987, McCluskey et al. also demonstrated the efficacy of corticosteroids
for the treatment of scleritis. All 14 of the patients in their cohort had an improvement on
pulsed methylprednisolone, though six required additional immunosuppression to achieve
quiescence (25). In a large retrospective study of 392 patients with non-necrotizing
anterior scleritis, Sainz de la Maza et al. demonstrated a 36.7% response rate to oral
NSAIDs (26). Successful response to treatment with NSAIDs was associated with
idiopathic diffuse or nodular anterior scleritis with a low degree of inflammation, with
idiopathic disease, and with no ocular complications. Among those on systemic
corticosteroids, 7.4% had a successful resolution of symptoms. Patients with a high
degree of inflammation were more likely to experience resolution of their scleritis on
corticosteroids. The authors recommended using NSAIDs as first-line therapy in patients
with no contraindications, and further recommended trialing a second NSAID if the
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patient is refractory to the first, in patients with a lower amount of inflammation. They
recommended using corticosteroids as a first-line patients in patients with greater
inflammation. Jabs et al. demonstrated that 30% of patients with scleritis responded to
NSAIDs, and that 50% percent of those with nodular anterior scleritis responded to
corticosteroids (8). They also recommended NSAIDs, specifically indomethacin, as a
first line agent, but cautioned that patients with posterior scleritis or necrotizing scleritis
may require corticosteroids. Agrawal et al. demonstrated the efficacy of flurbiprofen but
demonstrated that it was much less effective in patients with systemic autoimmune
disease (27). While patients with posterior scleritis are usually treated with
corticosteroids, one small series demonstrated the efficacy of indomethacin in posterior
scleritis (28).
Though most of these studies have looked at the efficacy of NSAIDs as a group or
as a non-selective NSAIDs, Bauer et al. assessed the efficacy of the selective COX-2
inhibitor celecoxib in the treatment of scleritis. Of the 24 patients in their cohort, 22
demonstrated clinical improvement. The authors recommended celecoxib as a treatment
because of the lower rate of gastrointestinal complications (29). Due to the demonstrated
efficacy of NSAIDs for scleritis, and the relatively benign side effect profile, oral
NSAIDs are overall considered first line therapy. However systemic corticosteroids may
be used as a first-line treatment in patients with contraindications to NSAID use (e.g.
renal disease, peptic ulcer disease, etc), patients with intolerable side effects or allergies
to NSAIDs, patients with necrotizing or posterior scleritis, and patients with a high
degree of inflammation.
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Topical steroids have also been used in the management of scleritis. A phase I/II
clinical trial of 32 patients was conducted to assess the efficacy of topical prednisolone
acetate. Of those who received topical steroids, 47% had successful resolution of
inflammation. The authors proposed using topical steroids as a first line treatment to
spare patients the side effects of systemic NSAIDs and steroids. However, others have
not considered topical steroids as a monotherapy for scleritis, though it may be useful in
episcleritis (8, 27). Agrawal et al. found no difference in the progression of disease in
patients on combination NSAID and topical corticosteroid therapy when compared with
NSAID therapy alone but proposed that it could help patients with pain (27).
Though topical NSAIDs have been used with some success in episcleritis, no
studies have looked at topical NSAIDs specifically for scleritis. Topical NSAIDs are
usually not used in acute scleritis due to the risk of scleral melt (30, 31).
Oral corticosteroid therapy has been a mainstay of scleritis therapy, but recent
data demonstrates efficacy for subconjunctival and sub-Tenon steroid injections among
patients with local, non-infectious, and non-necrotizing scleritis. In one study of 68 eyes
receiving up to 40 mg of subconjunctival triamcinolone acetonide, there was a 97%
response rate with 67% of patients remaining in remission after 24 months (32). In
another retrospective study of 38 eyes, 36 eyes had resolution within six weeks of
injection (33).
Immunomodulatory therapy (IMT) is utilized in patients who are refractory to
systemic NSAIDs and corticosteroids, as a method to wean patients off long-term steroid
use, provide an option for long-term management of ocular inflammation or to manage an
underlying systemic disease. In one study, 38% of patients with scleritis required

8
escalation to immunomodulatory therapy (26). In another study, 25% of patients with
scleritis required escalation to IMT therapy (8). Those with necrotizing scleritis were
more likely to require IMT, with 70% of these patients requiring systemic
immunomodulation for adequate scleritis control. These studies measured the prevalence
of the usage of IMT but did not assess the efficacy of any agents. Other studies have
assessed the individual efficacies of the most commonly used of these agents have been
studied. The largest of these studies were the systemic immunosuppressive therapy for
eye disease (SITE) studies, which were retrospective cohort studies that evaluated the
efficacy of several treatments for inflammatory eye diseases, including scleritis.
Methotrexate is an antimetabolite agent that inhibits folate metabolism (15). The
largest study evaluating its efficacy was a SITE study that included 384 patients (639
eyes) with inflammatory eye disease. This included 56 patients (84 eyes) with scleritis. In
their cohort, 38.6% of patients with scleritis treated with methotrexate at a median dose
of 12.5 mg/week as a single adjunct to systemic corticosteroid treatment achieved
absence of symptoms within 6 months of treatment and 37.3% achieved steroid-sparing
treatment success, defined as quiescence at a dose equivalent to 10 milligrams or less of
prednisone, within 6 months (34).
Other smaller studies have also evaluated the efficacy of methotrexate therapy for
scleritis. In one retrospective study of 17 patients on methotrexate, 61.9% of patients had
resolution of inflammation and symptoms at 3 months and 90.5% had a resolution of
symptoms at 12 months. Steroid-sparing success was achieved by 69.2% of patients
within 3 months and by 92.3% within 12 months (35). Another study of 39 patients with
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inflammatory eye disease, of which three had scleritis, reported that 79% of patients,
including all three with scleritis, had a full or partial response to methotrexate (36).
Mycophenolate mofetil, another antimetabolite drug, inhibits B and T cell
proliferation by inhibiting purine metabolism. Several studies have demonstrated the
efficacy of mycophenolate mofetil in the treatment of scleritis. A SITE study evaluated at
the efficacy of treatment with mycophenolate mofetil as a single non-corticosteroid
treatment in 236 patients with inflammatory eye disease, of which 33 had scleritis. Of the
patients with scleritis, 49% had an adequate treatment response within 6 months and
25.5% achieved steroid-sparing success (37). Other, smaller retrospective studies, as well
as case reports and case series, have reported successful treatment of scleritis with
mycophenolate mofetil. In one such study of four patients with scleritis on
mycophenolate, three patients were able to decrease their steroid dose (38). In another
study of 22 patients on mycophenolate, which included 20 patients who had failed
another IMT, all patients achieved resolution of inflammation and were able to decrease
their dose of corticosteroids (39). A case series of five patients with vasculitis associated
inflammatory eye disease, including one with scleritis, reported treatment success of a
patient with scleritis (40). Enteric-coated mycophenolate was demonstrated to be
efficacious at controlling symptoms in a retrospective review of five patients (41).
Other small studies have demonstrated the efficacy of mycophenolate specifically
as a steroid-sparing agent. In a study of 84 patients with inflammatory eye disease, of
whom 17% had scleritis, found that 82% of patients had steroid sparing resolution of
symptoms. The median time to steroid sparing success was 3.5 months (42). In another
retrospective study of 10 patients with inflammatory eye disease, including three with
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scleritis, resulted in steroid sparing in all patients, and decreased the average number of
relapses from 3.1 per patient per year to 0.8 per patient per year (P<0.005) (43. In a study
of four patients with active scleritis in which mycophenolate was added as an adjunctive
therapy to cyclosporine or methotrexate, it was not effective in these patients. This study
also included four patients with inactive scleritis on steroids who were given
mycophenolate as a steroid-sparing agent. The steroid dose was tapered by 50% in three
of these patients. The authors concluded that mycophenolate may be effective as a steroid
sparing agent, but not as an adjunctive immunosuppressant in active disease (44).
Other studies have demonstrated a negative effect of treatment with
mycophenolate, including lower rates of resolution of inflammation and increased
likelihood of relapse. One of these studies included 85 patients with inflammatory eye
disease, including seven with scleritis, who had previously failed methotrexate. Of those
who received mycophenolate, 55% of patients achieved remission and were able to be
taken off of medication. The authors also found, however, that treatment with
mycophenolate was negatively associated with resolution of inflammation on
mycophenolate (OR, 0.19; 95% CI, 0.04–0.93; P = 0.04) (45). Another study had a
similar finding. In this study of 114 patients with posterior scleritis, mycophenolate was
associated with accelerated time to relapse in a Cox proportional hazards model (20). The
authors speculated that more severe cases are put on mycophenolate, which may result in
the observed paradoxical effect, however they also point out that mycophenolate has been
associated with an increased risk of recurrence in other autoimmune disorders including
lupus nephritis and IgA nephropathy (46-48). Overall, studies evaluating mycophenolate
use in scleritis have had mixed results, with some demonstrating its efficacy in causing
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the resolution of scleritis, some demonstrating only a steroid-sparing benefit, and some
demonstrating a negative effect. Overall, most studies report a positive effect of
mycophenolate treatment.
Azathioprine is an antimetabolite prodrug of 6-mercaptopurine that inhibits B and
T lymphocytes by inhibiting purine metabolism (15). In a SITE study of patients with
scleritis treated with azathioprine as an adjunct to corticosteroids, 20% were controlled
within 6 months, and 47.8% of patients overall with inflammatory eye disease (not
stratified for scleritis) were successfully weaned to less than 10 mg of prednisone within
6 months (49). Though less studied than methotrexate or mycophenolate mofetil,
successful azathioprine use has been reported in multiple other studies, including in cases
of necrotizing scleritis, posterior scleritis, and vasculitis-associated scleritis (23, 50-52).
Calcineurin inhibitors function by inhibiting the transcription of interleukin-2 in T
lymphocytes, which decreases T cell activation. Cyclosporine A is one such calcineurininhibitor (15). It is most commonly used in scleritis associated with granulomatosis with
polyangiitis (13). The efficacy of systemic cyclosporine was first reported in a 1989 case
series in which five out of seven corticosteroid-refractory scleritis patients had a
resolution of symptoms when treated with cyclosporine (53). In another early study of
five patients, all five were successfully able to reduce corticosteroid dose upon initiation
of cyclosporine (54). In a case series of two patients with idiopathic scleritis, both
corticosteroid-refractory patients had a resolution of symptoms on systemic cyclosporine
(55). Another series of six patients with necrotizing scleritis were also successfully
treated with cyclosporine (56). In SITE study including 373 patients being treated with
cyclosporine A, 52.8% achieved remission within 6 months (57). This was the largest
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study evaluating the use of cyclosporine A in scleritis patients, though only 4% of
patients in the study (15 patients) had scleritis. The successful use of topical cyclosporine
for scleritis has also been reported (58). Tacrolimus, another calcineurin inhibitor has
been reported to be successfully used in the treatment of scleritis in both systemic and
topical forms (59-61). Subconjunctival injections of sirolimus, another calcineurin
inhibitor, have been reported to be successful in a small phase I/II clinical trial of five
patients with necrotizing scleritis (62).
Other large series examined the individual efficacy of other agents. One large
retrospective series of 215 patients with ocular inflammatory diseases, including 22.3%
of them with scleritis, reported that 30% of patients with scleritis treated with
cyclophosphamide were able to be weaned to low dose steroids within 6 months, and
60.5% within 12 months (63). In another study of 16 patients with corticosteroidrefractory necrotizing scleritis or peripheral ulcerative keratitis associated with RA,
cyclophosphamide and methotrexate were considered to be the most effective therapies
(64).
Biologics have also been studied for use in scleritis. The most commonly used
biologics for scleritis are TNF-a inhibitors, including the monoclonal antibodies
adalimumab, infliximab, and certolizumab and the soluble TNF receptor fusion protein
etanercept, as well as the CD20 inhibitor rituximab. A review of published studies
reporting biologic use in scleritis patients was conducted in 2015 (65). At that time there
were no clinical trials for biologic use for the treatment of scleritis. There were 30 case
reports and case series encompassing 80 patients who were treated with a biologic agent.
The biologic with the most reports was the TNF-a inhibitor infliximab, an agent that has
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successfully been used in other autoimmune diseases and has been FDA approved for
rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and
psoriatic arthritis (66). The use of infliximab in the treatment of scleritis was reported in
18 studies encompassing 47 patients. Of those cases, 14 were idiopathic, 14 were
associated with rheumatoid arthritis, and 19 were associated with inflammatory diseases
other than rheumatoid arthritis. Among patients on infliximab therapy, 96% of patients
had an improvement in either visual acuity or inflammation, 64% were able to reduce or
discontinue corticosteroids, and 36% were able to discontinue infliximab. Adalimumab,
another TNF-a inhibitor, is FDA approved for juvenile inflammatory arthritis, rheumatoid
arthritis, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and
plaque psoriasis (66). It is also approved for the treatment of non-infectious intermediate,
posterior and panuveitis in children over the age of 2 and for adults. Two cases were
reported of adalimumab use in scleritis, one in a patient with psoriasis and one with
rheumatoid arthritis. Both had resolution of inflammation (67, 68). Certolizumab is a
PEGylated TNF-a inhibitor. Pegylation increases the half-life and decreases the
immunogenicity of certolizumab (69). Only one case was reported of a patient on
certolizumab. The patient had successful resolution (18, 70). Etanercept is a soluble TNF
receptor fusion protein, unlike the other TNF-a inhibitors which are monoclonal
antibodies. It is FDA approved for rheumatoid arthritis, polyarticular JIA (psoriatic
arthritis, ankylosing spondylitis, and plaque psoriasis (66). In one study encompassing six
patients with rheumatoid arthritis- associated scleritis on etanercept, three of the patients
failed to respond and three had recurrence of ocular symptoms while on therapy.
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Etanercept was not effective in the control of scleritis, however it was effective in
controlling underlying rheumatoid arthritis symptoms (71).
Rituximab is a chimeric anti-CD20 monoclonal antibody. The use of rituximab in
the treatment of scleritis was reported in 10 studies encompassing 26 scleritis patients
treated with rituximab. This included 11 patients with vasculitis. All reported
improvement in scleritis symptoms. A phase I/II trial of rituximab found efficacy in 9 out
of 12 patients (16). The authors of this review concluded that infliximab and adalimumab
may be superior to etanercept, and that rituximab may be preferable for vasculitisassociated scleritis. A retrospective study that was not included in this review included 17
patients (26 eyes) with scleritis treated with infliximab, adalimumab, or both at separate
times. Of these, 15 patients (88%) achieved resolution of symptoms for two months or
greater (72).
Since the release of this review a number of other studies and case reports have
been published about the use of biologics in the treatment of scleritis. A SITE study
included 32 patients with inflammatory eye disease treated with adalimumab, including
nine patients with scleritis (73). Of the 15 patients with ocular inflammation, seven (47%)
had a resolution of symptoms. A case series reported two patients with necrotizing
scleritis successfully treated with adalimumab. One of these patients resolved on
adalimumab and methotrexate after failing mycophenolate and tacrolimus, the other
resolved on adalimumab after failing methotrexate (74). A case of Takayasu arteritisassociated scleritis was also reported to be treated successfully with adalimumab (75). A
prospective cohort study followed 43 patients with uveitis or scleritis on adalimumab or
infliximab for greater than 1 year. Resolution of symptoms was achieved in 91% of
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patients, with a median resolution time of 1.2 years. An adverse event was reported in
54% of patients, and 9% had a serious adverse event requiring cessation of therapy (76).
Several more recent studies report the efficacy of rituximab in scleritis use,
especially vasculitis-associated scleritis and necrotizing scleritis. In a study of 37 patients
with granulomatosis with polyangiitis-associated eye disease, including 20 patients with
scleritis, 86% had resolution of ocular symptoms in 6 months (77). In a series of 9
patients (12 eyes) with granulomatosis with polyangiitis- associated scleritis, all patients
achieved quiescence on rituximab. All patients had previously failed corticosteroids and
another IMT (78). In another retrospective study of 15 patients, 14 had a treatment
response to rituximab, including six patients with granulomatosis with polyangiitis (79).
In another study that included eight patients (12 eyes) with granulomatosis with
polyangiitis- associated necrotizing, all patients had an improvement of symptoms and
seven patients had resolution of symptoms (80). In a case series of three patients with
peripheral ulcerative keratitis, including two with concurrent necrotizing scleritis, two
patients received rituximab. Both patients that received rituximab had a treatment
response (81) A case report of necrotizing scleritis after pterygium surgery also reported
successful treatment on rituximab after failure of corticosteroids, azathioprine, and
cyclophosphamide (82).
Tocilizumab is a monoclonal antibody that targets interleukin-6 receptors, which
inhibits interleukin-6 mediated lymphocyte activation. Only one case report exhibited
success in treating a patient with giant cell arteritis- associated scleritis with tocilizumab
(83).
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Anakinra is a biologic agent that functions by inhibiting the interleukin-1
receptor. One pilot study evaluated the efficacy of anakinra in refractory-scleritis in 10
patients. Nine of the patients had complete quiescence of symptoms (84).
Though several studies have demonstrated the efficacy of biologics for the
treatment of scleritis, there have been reports of inflammatory eye disease that appears to
be paradoxically associated with biologic use. Etanercept in particular has been
implicated. A case series by Gaojoux-Viala et al. reported three rheumatoid arthritis
patients that developed scleritis temporally associated to etanercept administration. Each
of these patients had resolution of ocular inflammation upon discontinuation of
etanercept. The authors also conducted a systematic review and found 42 cases of
inflammatory eye disease associated with the use of etanercept, including eight with
scleritis. In 28 patients, withdrawal of etanercept resulted in resolution of symptoms, and
in six cases symptoms were exacerbated upon re-challenge with etanercept (85). Though
more commonly associated with etanercept, there have also been reports of inflammatory
eye disease associated with infliximab. A review reported 22 cases of infliximabassociated uveitis in the literature. There were no cases of infliximab-associated scleritis
(86).
Most of these studies have only looked at one agent, making it difficult to
compare the efficacy of treatment options. Few studies have made head to head
comparisons of the efficacy of different treatments or treatment classes. A recent
retrospective study looking at the SITE cohort compared outcomes in patients treated
with methotrexate and those treated with mycophenolate. It included 352 patients with
inflammatory eye disease, including 59 with scleritis. Survival analysis demonstrated a
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shorter time to success in patients on mycophenolate when compared with methotrexate.
Rates of success converged at the 9-month point. Prior to 9 months a higher proportion of
patients on mycophenolate had successful resolution (87). A retrospective cohort of 257
patients with inflammatory eye disease, of whom 23% had scleritis, compared the
efficacy of methotrexate, mycophenolate, and azathioprine. The authors found that the
median time to treatment success was four months for mycophenolate, 4.8 for
azathioprine, and 6.5 months for methotrexate, and they concluded that mycophenolate
controls inflammation faster than the other agents. They also found that patients on
azathioprine were more likely to have side effects, and to discontinue treatment due to
side effects, than those on methotrexate or mycophenolate. A retrospective cohort of 50
patients compared patients on cyclophosphamide with a pooled group of patients on other
IMTs (methotrexate, mycophenolate, azathioprine, and cyclosporine). They found no
significant difference between cyclophosphamide and other agents in remission rate,
relapse rate, steroid-sparing, or visual loss, but patients on cyclophosphamide were more
likely to develop leukopenia, hemorrhagic cystitis, and to discontinue medication due to
side effects (88).
Some studies have also described the rates of complications in patients with
scleritis. For example, one large series demonstrated 60% rate of complications among
patients with scleritis compared to 13.5% with episcleritis. There was a 0% rate of visual
decline in patients with episcleritis while 16% of patients with scleritis had visual loss
(8). Another retrospective review of 358 patients found that 47% of patients with scleritis
had a decrease in vision, peripheral ulcerative keratitis developed in 14%, glaucoma
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occurred in 13%, cataract formed in 17% and among patients with episcleritis 2%
developed decreased vision, 4% developed glaucoma, and 2% developed cataracts (22).
Few studies have compared prescribing practices of ophthalmologists and other
physician types. One study that surveyed 1044 uveitis specialists and rheumatologists,
with an 8.6% response rate, found that methotrexate was the most common IMT choice
for the treatment of anterior scleritis in both groups, but that uveitis specialists were more
likely than rheumatologists to prescribe mycophenolate (89).
Methods
The medical records of all patients with a CPT code for scleritis seen at Yale New
Haven Hospital, Yale Medicine, or the Yale Eye Center from January 1, 2013 to January
1, 2018 were reviewed. CPT codes used include ICD-10 codes H15.00-15.099 and ICD-9
codes 379.00-379.09. The medical records of patients diagnosed in this range were
retrospectively reviewed from January 1, 2013 to January 1, 2020. All patient
information was accessed through the electronic medical record. All data collection and
statistical analyses were performed by the author. The study protocol was approved by
the Yale Institutional Review Board (IRB).
Patient Categorization
Patients were divided into four subtypes of scleritis (diffuse anterior, nodular
anterior, necrotizing, or posterior) based on the classification system established by
Watson et al. (1). If the subtype was not specified, the subtype was defined based on the
clinical description.
Patients were categorized according to the likely etiology of scleritis: infectious,
postsurgical, posttraumatic, associated with systemic disease, or idiopathic. Those with
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positive testing for a viral or bacterial agent were defined as infectious. Patients were
defined as postsurgical or posttraumatic if there was a clear preceding surgical/traumatic
event prior to the onset of symptoms. Patients presenting with a postsurgical infection
were classified as infectious. If a patient received a diagnosis of a systemic autoimmune
disease before or after the onset of scleritis symptoms, their scleritis was considered to be
associated with a systemic disease. Idiopathic disease was a diagnosis of exclusion for
those who did not fall into the above categories.
Patients were also subdivided based on the specialty of the physician that
diagnosed and managed their scleritis. If a patient had an ophthalmologist involved in
their care who confirmed their diagnosis of scleritis they were classified in the
“ophthalmologist” category. This included patients who were being co-managed by
another provider type. This also included patients who did not have a flare in the
observation period of 2013 to 2018 but had previously had an episode of scleritis
confirmed by an ophthalmologist and were being actively monitored for recurrence.
These patients were included as having been confirmed by an ophthalmologist for
descriptive and demographic data but were not included in analysis related to a specific
episode of scleritis. If a patient had no active flare up of inflammation in the observation
period and was documented to have a history of scleritis, but the specialty of the
physician who made the diagnosis was not specified and they were not being monitored
for recurrence they were categorized as “historical.” If a patient did not have an
ophthalmologist involved in their care, they were classified according to the specialty of
the physician that diagnosed and managed their scleritis such as: primary care,
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emergency medicine, rheumatology, gastroenterology, general surgery, pulmonology,
and neurology.
Data Collected
Data collected included date of diagnosis, date of resolution, date of steroid
sparing resolution, recurrence of scleritis, treatments utilized (including start and end
dates), smoking history, adverse events, and comorbidities. Smoking status was
determined at the time of chart review. Data on comorbidities was manually collected
from patient charts and from the patient problem list. Comorbidities were subdivided into
ophthalmologic comorbidities, autoimmune comorbidities, and other comorbidities.
The “Other” comorbidities were used to assess the patients’ overall health status.
The Charlson Comorbidity Index was used to quantify the patient’s overall health status.
It was calculated as specified by Charlson et al. in 1987 (90). The Charlson Comorbidity
Index encompasses age, history of myocardial infarction, congestive heart failure (CHF),
peripheral vascular disease (PVD), chronic obstructive pulmonary disease (COPD),
peptic ulcer disease (PUD), chronic kidney disease (CKD), diabetes mellitus,
cerebrovascular accident (CVA) or transient ischemic attack (TIA), dementia, liver
disease (including cirrhosis and chronic hepatitis), hemiplegia/paraplegia, cancer
(including leukemia, lymphoma, solid tumors, and metastatic disease), and acquired
immunodeficiency virus.
Data was also collected on several comorbidities of interest not included in the
index. This included history of headache disorder, as scleritis can be misdiagnosed as a
headache disorder, as well as psychiatric history and substance abuse history as a

21
representative of the potential psychological toll of scleritis. Hypertension and
hyperlipidemia diagnoses were collected as markers of cardiovascular health.
Definitions
The date of diagnosis was defined as the first day in which there was documented
scleral inflammation. A patient’s scleritis was considered to have resolved if they had two
or more sequential visits in which they were reported to have achieved resolution of
symptoms using words such as “quiescence” or “resolved.” Charts were manually
searched for these terms. The first visit at which a patient had achieved resolution of
symptoms was used as the date of resolution. A patient was considered to have achieved
steroid sparing resolution if they were on a dose of 10 milligrams or less of prednisone,
or equivalent dosing for other steroids (e.g. dexamethasone, methylprednisolone,
prednisolone), without a recurrence of inflammation. A patient was considered to have a
new episode if they had new inflammation three or more months after their date of
resolution. Patients were defined as having an adverse event if a secondary condition was
directly attributed to an episode of scleritis.
Statistical Analysis
A range of analytical techniques were used, starting with univariate analysis
including chi-square, independent t-test, Pearson correlation, and ANOVA. Univariate
analysis was used to find associations with outcomes of interest including resolution,
steroid sparing resolution, recurrence, and complications, as well as associations between
demographic factors, comorbidities, and treatments. For categorical variables with more
than two levels, post hoc analysis was conducted using the Bonferroni correction. When
analyzing variables with small numbers, non-parametric testing such as the Mann-
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Whitney U was used. Multivariate regression was performed using binary logistic
regression to evaluate treatments and factors associated with resolution and steroid
sparing resolution. Cox proportionate hazards modelling was used to assess variables
associated with time to resolution and steroid sparing resolution. All analysis was
performed using Statistical Product and Service Solutions (SPSS) software (IBM,
Armonk, New York, USA).
Ethical Concerns
As this study was a retrospective review, the main ethical concern was that of
patient privacy. All identifiable patient information was managed in compliance with
HIPAA policies and handled only on secure, encrypted devices.
Results
465 patients with CPT codes for scleritis were identified from January 1, 2013 to January
1, 2018. Of those, 256 patients (302 eyes) had notes that corroborated their scleritis
diagnosis. The medical record for the remaining 209 patients had no notes that confirmed
a diagnosis of scleritis.
Descriptive Data and Univariate Analysis
Scleritis Subtypes
Patients were divided into four subtypes of scleritis based on the classification
system established by Watson et al. (1). Diffuse anterior scleritis was found in 232
patients (90.6%), nodular anterior scleritis in 10 patients (3.9%), necrotizing scleritis with
inflammation in two patients (0.8%), and necrotizing scleritis without inflammation
(scleromalacia perforans) in three patients (1.2%) (Table 1). Due to the small number of
patients, the two categories of necrotizing scleritis were clustered. One of the patients
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with diffuse anterior scleritis had a history of posterior scleritis but did not have both
types simultaneously.
Most patients had unilateral symptoms across subtypes. Overall, 210 patients
(82%) had unilateral disease and 46 (18%) had bilateral disease. There was a female
majority (65.5%) among patients with diffuse anterior scleritis. The female percentage of
nodular, necrotizing, and posterior scleritis were 50%, 60%, and 55.5%, respectively. The
difference in male to female ratio among these subtypes was not significant by ChiSquare testing.
Those with diffuse anterior scleritis were significantly younger than those with
other scleritis subtypes by the Student’s t-test, (p<0.05, mean difference -7.31, 95% CI [14.41, -0.203) (Table 1). When comparing the proportions above age 50 among subtypes
using Chi-Square with Bonferroni correction, those with diffuse scleritis were less likely,
to be older than age 50. Those with necrotizing scleritis more likely to be older than age
50. Patients with diffuse anterior scleritis had lower overall Charlson comorbidity scores
than those with other subtypes by t-test (p<0.001, mean difference -2.00, 95% CI [-3.00, 1.00]). When comparing across subtypes using 1-way ANOVA with Bonferroni
correction, those with diffuse anterior scleritis had significantly lower Charlson
comorbidity scores when compared to those with necrotizing scleritis (p<0.001, mean
difference -4.08, 95% CI [-6.90, -1.25])(Table 1). They also had lower scores than those
with nodular scleritis, but it was not significant (p<0.1, mean difference 1.98, 90% CI
[3.80, -0.15). Age may partially or fully explain this observation in comorbidity scores.
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Asian patients were more likely than Caucasian patients or Hispanic patients to
have nodular scleritis (p<0.01). There was no significant difference in the prevalence of
nodular scleritis between African Americans and other groups.
4 of the five cases of necrotizing scleritis were associated with an autoimmune
condition. One of these patients had granulomatosis with polyangiitis. Three of them (all
three that had scleromalacia perforans) had rheumatoid arthritis. Two of the three with
rheumatoid arthritis also had Sjogren’s syndrome.
Patients

Laterality

Gender

Age at

CCI

Presentation
Type of Scleritis

n

%

Unilateral

Bilateral

Male

Female

Mean

SD

Mean

SD

Diffuse Anterior

232

90.6

190

42

81

151

49.4*

17.12

2.13

2.19

Nodular Anterior

10

3.9

8

2

5

5

59.60

11.12

4.10

3.00

Necrotizing

5

2.0

4

1

2

3

58.40

6.35

6.20**

4.66

Posterior

9

3.5

8

1

4

5

52.56

18.28

3.00

3.81

Total

256

210

46

92

164

Table 1 Subtypes of scleritis; CCI= Charlson Comorbidity Index; *p<0.05 compared to
other groups and significant after Bonferroni correction; **p<0.05 compared to diffuse
anterior scleritis.
Etiologies
Of the 256 patients, 146 (57%) had idiopathic disease, 90 (35.2%) had disease
associated with a systemic autoimmune disease, seven (2.8%) presented after
ophthalmologic surgery, seven (2.8%) presented after suspected ocular trauma, and seven
(2.7%) were infectious (Table 2). Due to the similarity of traumatic and surgical
etiologies, these two categories were clustered. Some cases were double counted. For
example, two patients that developed scleritis after suspected ocular trauma also had a
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systemic autoimmune disease (one with rheumatoid arthritis and granulomatosis with
polyangiitis, the other with Grave’s disease), as did one of the patients with a herpes
simplex infection (rheumatoid arthritis, on immune suppression).
Patients

Laterality

Gender

Age at
Presentation

Etiology

n

%

Unilateral

Bilateral

Male

Female

Mean

SD

Infectious

12

4.7

12

0

2

10

58.9

15.3

Postsurgical/

14

5.5

14

0

7*

7

54.0

17.3

90

35.2

69

21

21

69*

51.8

15.4

Idiopathic

146

57

121

25

62

84*

48.5

17.5

Total

256

210

46

138

119

posttraumatic
Associated with
systemic disease

Table 2 Scleritis etiology; *p<0.05, representing the group with the higher proportion.
Cases of infectious scleritis were caused by herpes simplex virus (HSV) in seven
patients. (2.7%), by varicella zoster virus (VZV) in two patients (0.8%), by
Pseudomonas aeruginosa in two patients (0.8%), and by Mycobacterium tuberculosis in
one patient (0.4%).
There was a gender relationship with several of the etiologies of scleritis. In those
with idiopathic disease there was a significantly higher percentage of females (57.5%) by
Chi-square testing (p<0.05) (Table 2). The association with female gender was stronger
among those with a systemic disease. Among patients with a systemic autoimmune
association 76.7% were female (p<0.005) (Table 2). Five of the seven patients who had
scleritis secondary to a procedure were female. This was not statistically significant.
Males were more likely than females to have scleritis associated with a traumatic event
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(71.4%, p<0.05) (Table 2). Infectious scleritis was more common in females (83.3%).
This included all seven of those infected with HSV, which was statistically significant by
Chi-square (p<0.05). There was no racial difference among etiologies of scleritis.
Demographics
Gender
64.1% of patients in our sample were female and 35.9% of patients were male (ztest, p<0.001). Chi-square testing was used to evaluate the gender proportions among
patients with autoimmune diseases. Autoimmune diseases assessed included rheumatoid
arthritis, lupus, inflammatory bowel disease, Sjogren’s syndrome, psoriasis,
granulomatosis with polyangiitis, Hashimoto’s thyroiditis, and Graves’ disease (see Table
4 in the Autoimmune Comorbidities section). Gender proportions were also evaluated
across other demographic factors including race, age, and smoking status. For categorical
variables with more than two levels, post-hoc analysis was conducted using the
Bonferroni correction.
The results of this analysis demonstrated that presence of any comorbid
autoimmune disease was significantly associated with being female (43.5% of female
patients compared with 23.8% of male patients, p<0.005). Among the specific
autoimmune diseases, lupus was significantly associated with female gender (6.1% of
female patients compared to 0% of male patients had lupus, p<0.05) as was Sjogren’s
syndrome (7/7 patients were female, p<0.05) (see Table 4 in the Autoimmune
Comorbidities section). Rheumatoid arthritis, inflammatory bowel disease, psoriasis,
granulomatosis with polyangiitis, Hashimoto’s thyroiditis, and Graves’ disease were not
associated with gender. Each of these diseases, with the exception of granulomatosis with
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polyangiitis included more female patients than male patients but given the initial gender
skew in our sample the differences were not significant.
Among demographic factors, male patients were more likely to be current
smokers (22.8% of male patients compared to 10.4% of female patients, p<0.05). There
was no difference in the rate of former smokers. There were no significant relationships
with race and gender. There was a higher proportion of Hispanic patients that were
female compared to other patients (77.8% female versus 63% female), but it did not reach
significance (p<0.1). There was no significant difference in mean ages by t-test
(p=0.819). The mean age for female patients was 50.27+/-15.94 compared to 49.76 +/18.64 for male patients.
There was no association between gender utilization of any of the treatments
including systemic NSAIDs, topical NSAIDs, systemic steroids, topical steroids, subTenon’s triamcinolone acetonide, or any of the immunomodulatory therapies.
Race
In our sample, 48.4% of patients were Caucasian, 27.8% were African American,
18.4% were Hispanic, 2.4% were Asian, and 0.8% were other (Figure 1). Caucasian
patients were more likely to have a comorbid autoimmune disease (44.4% of Caucasian
patients compared to 27.3% of non-Caucasian patients, p<0.005). Caucasian patients
were also more likely to have inflammatory bowel disease than non-Caucasian patients
(13.7% compared to 2.5%, p<0.005). Rheumatoid arthritis, inflammatory bowel disease,
psoriasis, granulomatosis with polyangiitis, Hashimoto’s thyroiditis, and Graves’ disease
were not associated with race.
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Figure 1 Racial demographics in scleritis patients
There was no association between race and utilization of any of treatments
including systemic NSAIDs, topical NSAIDs, systemic steroids, topical steroids, subTenon’s triamcinolone acetonide, or any of the immunomodulatory therapies or classes of
immunomodulatory therapies.
Age
Age at diagnosis ranged from 3 to 93, with a mean age of 50.1 +/- 16.9. The age
distribution is bimodal, with one peak at 28 years of age and another, larger peak at 52
years (Figure 2). This may indicate that there is a smaller, younger subpopulation within
the sample as a whole. Hispanic patients were younger than Caucasian patients at time of
diagnosis, but this was not significant [p<0.1, mean difference -6.326, 90% CI [-12.61,
0.04]. There were no other notable differences between races in age.
Patients diagnosed with Sjogren’s syndrome were significantly older at the time
of scleritis diagnosis than those without Sjogren’s syndrome p<0.005, mean difference
17.243, 95% CI [4.621, 29.865]). The difference is still significant when comparing those
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with Sjogren’s against those with other autoimmune diseases (p<0.05, mean difference
16.4, 95% CI [2.26, 30.47]) (see Table 4 in the Autoimmune Comorbidities section).
Those with rheumatoid arthritis were also significantly older than those without
rheumatoid arthritis (p<0.05, mean difference 6.619, 95% CI [0.598, 12.640]). No other
systemic autoimmune diseases were significantly associated with age.

Figure 2 Histogram of patients’ age at the time of scleritis diagnosis.
Those who received systemic NSAIDs were significantly younger than those who
did not (p<0.005, mean difference -7.513, 95% CI [11.821, -3.204]). Though only
significant at the 90% confidence interval, those on TNF-⍺ inhibitors were on average
younger at time of diagnosis than those on other non-corticosteroid immunomodulatory
therapies (p<0.1, mean difference -9.304, 90% CI [-18.30, -0.31]). Patients on TNF-⍺
inhibitors were not significantly younger than those not on a non-corticosteroid
immunomodulatory therapy.
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Comorbidities
Ophthalmologic Comorbidities
60 patients had an ophthalmologic disease other than scleritis (Table 3). The most
common of these, present in 15.6% of patients, was uveitis. This included 34 patients had
anterior uveitis, one had pars planitis, and five had panuveitis. The next most common
comorbidity was glaucoma in 6.3% of patients. Other comorbidities were present in small
numbers, with one patient with keratitis, two with filamentary keratitis, two with retinitis
pigmentosa, one with retinoschisis, one with recurrent corneal degeneration syndrome,
one with keratoconus, and four with phthisis bulbi. This does not include comorbidities
directly attributed to scleritis or its treatment (see patient outcomes). Some patients had
multiple ophthalmologic comorbidities. Seven with uveitis also had another diagnosis.
This included four patients with anterior uveitis and glaucoma, one patient with comorbid
anterior uveitis and filamentary keratitis, and one with panuveitis and glaucoma. There
was also one patient with filamentary keratitis, one with macular degeneration, and one
with retinoschisis who also had comorbid glaucoma.
There was no correlation by Chi-square between comorbid uveitis and the
presence of systemic autoimmune disease (p=0.485). There was also no gender
correlation. There was no significant association between comorbid uveitis and age at
scleritis diagnosis by independent t test. Patients with anterior uveitis were older at the
time of their scleritis diagnosis than those with pars planitis or panuveitis, by 5.52 years
and 4.12 years, respectively, but this difference was not statistically significant. African
American patients were more likely than others to have concurrent uveitis, but the
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difference was not statistically significant (25% of African Americans compared to
13.7% of Caucasians, 6.7% of Asians, and 0% of Hispanic patients).
Due to the small number of patients with other comorbidities, nonparametric
testing was used to assess their associations with other factors. Patients with comorbid
glaucoma were older at the time of scleritis diagnosis than those without glaucoma by
Mann-Whitney U testing (p<0.1, test mean difference 7.557, 90% CI [0.147, 14.967).
Patients with macular degeneration were also older at the time of scleritis diagnosis at the
95% confidence by Mann-Whitney U testing (p<0.05, mean difference 27.126, 95% CI
[7.449, 46.803]) (Table 3). Other comorbidities were not significantly associated with
age.
Patients with posterior scleritis were more likely to have glaucoma (13.3% vs.
2.9%, p=0.05). Patients with comorbid retinitis pigmentosa were also significantly more
likely to have posterior scleritis (50% of those with retinitis pigmentosa compared to
3.1%, p<0.005), as were patients with phthisis bulbi (25% compared to 3.2%, p<0.05)
and with comorbid filamentary keratitis (50% compared to 3.1%, p<0.005). Other
comorbidities were not significantly associated with scleritis subtype.
None of the ophthalmologic comorbidities, including inflammatory eye diseases
such as keratitis and uveitis, were associated with systemic autoimmune disease or with
gender.
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Ophthalmologic

Patients

Gender

Age at Scleritis Diagnosis

Comorbidity
n

%

Male

Female

Mean

SD

Uveitis

40

15.6

19

21

52.08

14.95

Anterior Uveitis

34

13.3

15

19

53.12

15.33

Pars planitis

1

0.4

1

0

39

0

Panuveitis

5

2.0

3

2

47.60

12.80

Keratitis

1

0.4

1*

0

42.67

28.22

Filamentary

2

0.8

2

0

50

36.77

Glaucoma

15

5.9

9

7

57.38

14.36

Macular

2

0.8

1

1

77*

7.07

2

0.8

0

2

33.50

19.09

Retinoschisis

1

0.4

0

1

77

0

Recurrent corneal

1

0.4

0

1

52

0

Keratoconus

1

0.4

0

1

43

0

Phthisis bulbi

4

0

4

53.00

11.92

Keratitis

Degeneration
Retinitis
pigmentosa

degeneration
(RCE) syndrome

Table 3 Ophthalmologic comorbidities in scleritis patients; *p<0.05 when
compared to pooled other groups.
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Autoimmune Comorbidities
90 patients had scleritis associated with a systemic autoimmune disease (Table 4).
The mean age of the patients with systemic autoimmune disease was 49.7 years, which
was not significantly different than the age of those without a systemic autoimmune
disease. The most common of these was rheumatoid arthritis in 14.5% of patients.
Inflammatory bowel disease was a comorbidity in 7.8% (5.1% with Crohn’s disease and
2.7% with ulcerative colitis), lupus erythematosus in 3.5% (systemic in 3.1% and discoid
in 0.4%), psoriasis in 3.5%, autoimmune thyroid disease in 3.1% (Hashimoto’s thyroiditis
in 2.3% and Graves’ in 1.2%), Sjogren’s syndrome in 2.7%, and granulomatosis with
polyangiitis in 2.0%. Ankylosing spondylitis, scleroderma, autoimmune hepatitis,
polyarteritis nodosa, polymyositis, and mixed connective tissue disorder each had one
patient (0.4%). Seven patients were identified as “unspecified” if they were noted by their
ophthalmologist or rheumatologist to have “autoimmune” or “inflammatory” arthritis or
spondyloarthropathy, but the specific diagnosis was not listed at the time of review.
16 patients had more than one systemic autoimmune disease at the time of
diagnosis, including 12 who had been diagnosed with two diseases and four who had
been diagnosed with three diseases. Those who were diagnosed with two concurrent
diseases included: three patients with concurrent rheumatoid arthritis and Sjogren’s
syndrome, one with rheumatoid arthritis and ankylosing spondylitis, one with rheumatoid
arthritis and antiphospholipid syndrome, one with an unspecified inflammatory arthritis
and Sjogren’s syndrome, one with granulomatosis with polyangiitis and Hashimoto’s
thyroiditis, one with Crohn’s disease and Sjogren’s syndrome, one with Crohn’s disease
and polyarteritis nodosa, one with systemic lupus erythematous and ulcerative colitis, one
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with systemic lupus erythematous and Crohn’s disease, and one with discoid lupus and
ankylosing spondylitis. Those who were diagnosed with three concurrent diseases
included: a patient with systemic lupus erythematous, Hashimoto’s thyroiditis, and
Sjogren’s syndrome, a patient with rheumatoid arthritis, autoimmune hepatitis, and
polymyositis, a patient with rheumatoid arthritis, Hashimoto’s thyroiditis, and Sjogren’s
syndrome, and a patient with rheumatoid arthritis, mixed connective tissue disorder, and
Sjogren’s syndrome. Having more than one systemic autoimmune disease was associated
with bilateral scleritis by chi-square analysis then compared to those with only one
autoimmune disease (37.5% compared to 25.4%, p<0.05).
Some autoimmune diseases were associated with demographic factors such as
race, gender, or age, as specified above in the demographics section.
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Patients

Laterality

Gender

Age at Presentation

More than one systemic condition

Associated Systemic Disease

n

%

Unilateral

Bilateral

Male

Female

Mean

SD

Yes

No

Rheumatoid Arthritis

37

14.5

28

9

8

29*

56.6*

14.7

9

28

Inflammatory Bowel Disease

20

7.8

18

2

6

14

44.8

16.2

4

16

Crohn’s disease

13

5.1

12

1

3

10

45.2

15.8

3

10

Ulcerative Colitis

7

2.7

6

1

3

4

44.0

18.1

1

6

Psoriasis

9

3.5

7

2

6

3

46.3

10.1

2

7

Lupus erythematosus

9

3.5

5

4

0

9

41.1

15.5

2

7

Systemic

8

3.1

4

4

0

8

42.0

16.3

2

6

Discoid

1

0.4

1

0

0

1

34

0

0

1

Thyroid Disease

8

3.1

4

5

5

4

48.6

14.2

3

6

Hashimoto’s thyroiditis

6

2.3

2

4

5

1

55

12.6

3

3

Graves’ disease

3

1.2

2

1

0

3

35.7

6.7

0

3
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Sjogren’s syndrome

7

2.7

4

3

0

7*

66.9*

2.9

7

0

Granulomatosis with polyangiitis

5

2

1

4

2

3

62.4

20.0

2

3

Ankylosing Spondylitis

2

0.8

0

2

1

1

39

0

0

2

Scleroderma

1

0.4

1

0

0

1

43

0

0

1

Autoimmune hepatitis

1

0.4

1

0

0

1

59

59

1

0

Polyarteritis nodosa

1

0.4

1

0

0

1

31

0

1

0

Polymyositis

1

0.4

1

0

0

1

59

59

1

0

Multiple connective tissue disorder

1

0.4

1

0

1

0

77

0

0

1

Unspecified spondyloarthropathy/

7

2.7

6

1

2

5

50.1

12.3

0

7

inflammatory arthritis

Table 4 Systemic autoimmune comorbidities in scleritis patients; *p<0.05 compared against pooled other groups.

37
Overall Health Status
Data on comorbidities other than systemic autoimmune disease or ophthalmologic
disease is summarized in Table 5. The most common comorbidities were hypertension
(40.6%), hyperlipidemia (26.6%), diabetes mellitus (17.6%), and psychiatric
comorbidities (23.8%). At least one psychiatric comorbidity was diagnosed in 61 patients
(23.8%). By z-test, this is a significantly higher than the 18.9% reported in the 2017 data
released by the National Institutes of Mental Health (91). The most common of them was
major depression (16.8%) followed by an anxiety disorder (12.5%). More than one
psychiatric comorbidity was diagnosed in 38 patients (14.8%).
One of the patients with hepatitis C was suspected to have cryoglobulinemia as an
etiologic factor for their scleritis. Three of the patients with chronic kidney disease
developed it secondary to lupus nephritis.
Asthma was seen in 14.1% of patients, which is notably higher than the CDC
reported proportion of asthma in adults in the United States (7.7%) (p<0.05). Asthma was
correlated with the presence of a systemic autoimmune disease (p<0.05).
Due to the small number of patients for most comorbidities, nonparametric testing
was used to evaluate potential associations. Female gender was significantly associated
by Chi-square testing with a higher probability of having asthma (p<0.01), a headache
disorder (p<0.005), or major depression (p<0.05). Male gender was associated with a
higher probability of a history of myocardial infarction, peripheral vascular disease
(p<0.05), and opiate use disorder (p<0.05).
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Patients

Chronic Kidney Disease

14

5.5

Hematologic Disease

3

1.2

Comorbidity

n

%

Cardiovascular Disease

36

14.1

Immune thrombocytopenic purpura

2

0.8

Myocardial Infarction

7

2.7

Sickle cell trait

1

0.4

Coronary artery disease

8

3.2

Peptic Ulcer disease

5

2.0

Congestive Heart Failure

3

1.2

Hemiplegia/paraplegia

1

0.4

Diabetes Mellitus

45

17.6

Peripheral vascular disease

3

1.2

Hyperlipidemia

68

26.6

Hypertension

104

40.6

Cancer

44

17.2

Leukemia

5

2.0

Lymphoma

2

0.8

Solid tumors

37

14.8

Solid tumor with metastases

2

0.8

Psychiatric Comorbidities

61

23.8

Depression

43

16.8

Bipolar Disorder

10

4.0

Anxiety Disorder

32

12.5

Schizophrenia

3

1.2

Neurological Comorbidities

28

21

Cerebral Vascular Accident

10

3.9

Dementia

2

0.8

Headache

16

6.3

Liver Disease

7

2.8

Cirrhosis

2

0.8

Chronic hepatitis C

2

0.8

Nonalcoholic fatty liver disease

3

1.2

Pulmonary disease

48

18.8

Obsessive Compulsive Disorder

2

0.8

Chronic Obstructive Pulmonary

8

3.1

Posttraumatic stress disorder

5

2.0

Opiate use disorder

3

1.2

Disease
Asthma

36

14.1

Cocaine use disorder

5

2.0

Interstitial lung disease

4

1.6

Alcohol use disorder

6

2.4

Table 5 Comorbidities reflecting scleritis patients’ overall health status.
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Many comorbidities were associated with higher age, including peptic ulcer
disease, myocardial infarction, hypertension, hyperlipidemia, cerebrovascular event,
dementia, malignancy, diabetes mellitus, chronic kidney disease, and chronic obstructive
pulmonary disease.
There was a significant positive association between necrotizing scleritis and
history of cocaine use (p<0.005), liver cirrhosis (p<0.005), interstitial lung disease
(p<0.005), history of myocardial infarction (p<0.05), and diabetes mellitus (p<0.05).
Posterior scleritis was significantly positively associated with diabetes mellitus (p<0.05),
history of opiate use disorder (p<0.005), cocaine use (p<0.005), peripheral vascular
disease (p<0.005), and nonalcoholic fatty liver disease (p<0.05). Nodular scleritis was
significantly positively associated with COPD (p<0.05), cancer (p<0.005), and
nonalcoholic fatty liver disease (p<0.05). Diffuse anterior scleritis was negatively
associated with alcohol use disorder (p<0.05), diabetes (p<0.005), cocaine use (p<0.005),
COPD (p<0.05), and nonalcoholic fatty liver disease (p<0.05)
The Charlson Comorbidity Index was used as a summary statistic for the overall
health condition of patients. The mean Charlson Comorbidity Index scores was 2.28 +/2.44 with a range of 0 to 12. There was a distinct rightward skew (Figure 3). There was a
strong positive correlation between the Charlson comorbidity index score (Pearson
coefficient 0.705, p<0.001), indicating that older patients had more comorbidities.
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Figure 3 Histogram of the distribution of Charlson Comorbidity Index scores among
scleritis patients.
Patients were classified as being primarily managed by ophthalmology if their
scleritis was solely managed by an ophthalmologist or if they were being jointly managed
by an ophthalmologist and another provider. Patients were classified as being managed
by emergency medicine if they presented to the emergency room with an episode of acute
scleritis without evidence in the medical record of specialty consultation or outpatient
follow-up. Patients were classified as being managed by other specialties (i.e.
rheumatology, primary care, etc.), if they were managed by a provider from that specialty
without evidence in the medical record of the involvement of an ophthalmologist in their
care.
Physician Specialty
Multiple specialties were involved in the management of the scleritis patients in
our sample. The majority of patients (67.2%) had an ophthalmologist involved in their
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care. Emergency medicine diagnosed and managed 5.9% of patients. These patients were
not seen by a consulting service and did not have outpatient follow-up. Rheumatology
managed 4.6% of patients and primary care managed 6.3%. Other specialties, including
gastroenterology, general surgery, pulmonology, and neurology, managed 4.3% of
patients. These specialties were clustered due to the small number of patients in each
category. These patients had no evidence of the involvement of an ophthalmologist in
their care in the medical record. The remaining 8.2% were classified as historical. These
were patients who had a documented history of scleritis but were not being followed or
monitored for scleritis by any physician and had no active episodes during the
observation period (Table 6).
Chi-square analysis with Bonferroni correction was used to compare proportions
of each scleritis subtype and etiology by medical specialty. Patients seen by a primary
care physician were significantly more likely than those seen by a rheumatologist to have
idiopathic disease (p<0.05). Rheumatologists were more likely to see patients with
systemic autoimmune associations than ophthalmologists (p<0.05) or primary care
(p<0.05). All patients with necrotizing or posterior scleritis were seen and managed by an
ophthalmologist, and 9 of the 10 patients with nodular scleritis were seen by an
ophthalmologist, however this was not statistically significant after implementing
Bonferroni correction.
Of the 90 patients with a systemic autoimmune correlation for their scleritis, most
were seen by an ophthalmologist (61.1%) or followed by rheumatology alone (15.6%).
An ophthalmologist was involved in the care of 62% of rheumatoid arthritis patients,
70% of inflammatory bowel disease patients, 67% of psoriasis patients, 89% of lupus
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patients, 38% of thyroid disease patients, 57% of Sjogren’s syndrome patients, 50% of
ankylosing spondylitis patients, and 40% of granulomatosis with polyangiitis patients. An
ophthalmologist was also a part of the care for the only patients with scleroderma,
autoimmune hepatitis, polymyositis, and mixed connective tissue disorder. With the
exception of one patient, scleritis associated with inflammatory bowel disease was
managed either by ophthalmology or gastroenterology (Table 7). Only two patients with
a systemic association were managed by primary care, one with psoriasis and one with
Hashimoto’s thyroiditis. Three patients with rheumatoid arthritis-associated scleritis and
two patients with autoimmune thyroid disease were acutely managed by an emergency
medicine physician without outpatient follow-up.
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Patients

Subtype

Etiology

Specialty

n

%

Diffuse

Nodular

Necrotizing

Posterior

Idiopathic

Systemic

Infectious

Posttraumatic

Ophthalmology

173

67.2

150

9

5

9

100

55

6

12

Rheumatology

19

4.6

19

0

0

0

6

14*

0

0

Emergency

15

5.9

15

0

0

0

9

5

0

14

Primary Care

16

6.3

16

1

0

0

13*

2

1

0

Other

11

4.3

11

0

0

0

6

5

0

0

Historical

21

8.2

21

0

0

0

12

9

0

0

232

10

5

9

146

90

7

14

Medicine

256

Table 6 Scleritis subtypes and etiologies seen by providers from different medical specialties; systemic refers to the presence
of a systemic autoimmune comorbidities; *p<0.05 when compared to patients seen by ophthalmology.
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Associated Systemic

Patients

Specialty

n

%

Ophthalmology

Rheumatology

Primary Care

Emergency Medicine

Other

Historical

37

14.

23

7

0

3

1

3

Disease

Rheumatoid Arthritis

5

Inflammatory Bowel

20

7.8

14

1

0

0

3

2

Crohn’s disease

13

5.1

10

0

0

0

3

0

Ulcerative Colitis

7

2.7

4

1

0

0

0

2

Psoriasis

9

3.5

6

1

1

0

0

1

Lupus erythematosus

9

3.5

8

1

0

0

0

0

Systemic

8

3.1

7

1

0

0

0

0

Discoid

1

0.4

1

0

0

0

0

0

Thyroid Disease

8

3.5

3

1

1

2

1

1

Hashimoto’s thyroiditis

6

2.3

1

1

1

1

1

1

Disease
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Graves’ disease

3

1.2

2

0

0

1

0

0

Sjogren’s syndrome

7

2.7

4

3

0

0

0

0

Vasculitis

6

2.4

2

2

0

0

0

2

Granulomatosis with

5

2

2

1

0

0

0

2

Polyarteritis nodosa

1

0.4

0

1

0

0

0

0

Ankylosing Spondylitis

2

0.8

1

1

0

0

0

0

Scleroderma

1

0.4

1

0

0

0

0

0

Autoimmune hepatitis

1

0.4

1

0

0

0

0

0

Polyarteritis nodosa

1

0.4

0

1

0

0

0

0

Polymyositis

1

0.4

1

0

0

0

0

0

Multiple connective

1

0.4

1

0

0

0

0

0

7

2.7

5

2

0

0

0

1

polyangiitis

tissue disorder
Unspecified
spondyloarthropathy/
inflammatory arthritis
Total

90

Table 7 Systemic autoimmune diseases seen by providers from different medical specialties.
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Treatments utilization differed based on the medical specialty involved in care
(Table 8). The most common agent used by ophthalmologists were topical steroids
(61%), followed by systemic NSAIDs (53%), and systemic steroids (38.7%). The most
common non-corticosteroid IMTs were methotrexate (18.5 %) followed by
mycophenolate (9.2%) and adalimumab (7.4%). The most common agent used by
rheumatologists was systemic steroids (40%) followed by methotrexate (35%) and
azathioprine (20%). The most common agents used by emergency medicine were
systemic NSAIDs (33%), particularly ketorolac (13%), which was not used by any other
specialties (significantly more likely to be used in the emergency department than by
ophthalmology, p<0.05), followed by topical steroids (20%). The most common agents
used by primary care were various anti-infectious agents (25%), including topical
trimethoprim-polymyxin B, tobramycin, and moxifloxacin. Fewer than half of those seen
by primary care (43.8%) received any treatment.
Patients seen by ophthalmologists were overall more likely to receive acute
treatment than those not seen by ophthalmologists (p<0.05). Patients seen by
ophthalmologists were significantly more likely than those seen by primary care to
receive systemic NSAIDs (43% compared to 0%, p<0.05) or systemic steroids (38.7%
compared to 0%, p<0.05). They were significantly more likely than those seen by other
specialties to received topical steroids (p<0.05) and they were more likely to receive a
non-corticosteroid immunomodulatory agent than those seen by primary care (40.4%
compared to 0%, p<0.05).
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Specialty

Patients

Treatment Type

n

Topical

Systemic

Topical

Systemic

NSAID

NSAID

Steroid

Steroid

%

MTX

MMF

LEF

AZA

INX

ADM

RIX

Ophthalmology

173

67.2

8

75*

106*

67*

32

16

5

6

5

13

5

Rheumatology

20

4.6

0

5

3

8

7

1

0

4

0

0

0

Emergency

15

5.9

0

5

3

1

1

0

0

0

0

0

0

Primary Care

16

6.3

1

0

2

0*

0

0

0

0

0

0

0

Other

11

4.3

0

0

1

6

1

0

0

0

0

0

0

Historical

21

8.2

0

2

0

5

3

0

0

1

0

0

1

Medicine

Table 8 Treatment utilization by medical specialty (methotrexate=MTX, mycophenolate mofetil= MMF, leflunomide=LEF,
azathioprine=AZA, infliximab=INX, adalimumab=ADM, rituximab=RIX); *p<0.05 compared to other groups.
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The difference in the rate of IMT use between those seen by rheumatologists
alone compared to those seen by ophthalmology was not statistically significant after
Bonferroni correction, and there was no statistically significant difference in specific IMT
agents.
Treatments Utilized
Many treatments were utilized in the treatment of scleritis (Table 9). The most
common overall were topical corticosteroids in 44.9% of patients. Topical corticosteroids
utilized include prednisolone, difluprednate, dexamethasone-neomycin-polymyxin B,
loteprednol, and fluorometholone. The next most common treatments were systemic
corticosteroids (34%) and systemic NSAIDs (34%). Systemic corticosteroids utilized
included prednisone, oral methylprednisolone, systemic methylprednisolone, and
budesonide. Systemic NSAIDs used included naproxen, ibuprofen, indomethacin,
meloxicam, diclofenac, piroxicam, flurbiprofen, sulindac, and celecoxib. Both systemic
NSAIDs and systemic steroids were used in 21 patients (8.2%), systemic NSAIDs and
topical steroids were used in 42 patients (16.4%), and systemic steroids and topical
steroids were used in 36 patients (14.1%). This includes the 11 patients (4.3%) that
received systemic steroids, systemic NSAIDs, and topical steroids during their treatment
course.
Topical NSAIDs were used in nine patients. Topical NSAIDs used included
flurbiprofen, ketorolac, nepafenac, and bromfenac. No patients received a topical NSAID
as monotherapy. Topical methotrexate drops were used in one patient. A Sub-Tenon’s
triamcinolone acetonide injection was needed in 11 patients (2.4%).
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Many non-corticosteroid immunomodulatory agents were used. At least one IMT
was required in 101 patients (39.5%), and 23 (8.9%) received more than one. This
included 31 patients (12.1%) that were on an IMT when their episode of scleritis started.
An antimetabolite was used in 32% of patients, with methotrexate (17.2%),
mycophenolate (6.8%) and azathioprine (4.7%) being the most common. Other
antimetabolites used included leflunomide and 6-mercaptopurine. These two agents were
used for those with a systemic autoimmune disease and were not used in any of the
patients with idiopathic disease.
14.4% of patients received a biologic agent, most commonly a TNF-⍺ inhibitor
(9.1%). This included 13 patients (5.1%) who received adalimumab, five patients (2%)
that received infliximab, four patients (1.6%) that received etanercept, and one patient
(0.4%) that received certolizumab. Six patients (2.4%) received rituximab. Other
biologics used included IVIG, anakinra, vedolizumab, tocilizumab, and tofacitinib. The
only biologics used in those with idiopathic disease were TNF-⍺ inhibitors. The other
biologics were used in those with systemic autoimmune associations.
Other non-corticosteroids IMTs utilized included the calcineurin inhibitors
cyclosporine and tacrolimus and the alkylating agent cyclophosphamide. These were only
used in one patient each. Cyclosporine and cyclophosphamide were used to manage an
underlying autoimmune disease. Tacrolimus was used for a patient with idiopathic
disease for transplant rejection after a kidney transplant.
A 5-aminosalicylate agent (mesalamine or sulfasalazine) was used in 11 patients
(5.4%). One of the patients on mesalamine received it for idiopathic disease. The other 10
received it for an associated systemic autoimmune disease. This included the other five
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patients on mesalamine who had Crohn’s disease, and five patients on sulfasalazine for
rheumatoid arthritis. Hydroxychloroquine was used in 13 patients (5.1%), 11 of whom
received it for an underlying systemic autoimmune disease and two of whom received it
for idiopathic disease.
Systemic steroids were used in all patients with necrotizing scleritis. Patients with
Patients with necrotizing scleritis were significantly more likely to receive systemic
steroids than patients with other subtypes of scleritis (p<0.005). They were also
significantly more likely to receive sulfasalazine (p<0.005) and leflunomide (p<0.005),
which were used to manage an underlying systemic disease. Patients with nodular
scleritis were significantly more likely to receive sub-Tenon’s triamcinolone injection
(p<0.005).
Patients with idiopathic disease were significantly more likely to receive systemic
NSAIDs (p<0.01). Patients with a systemic autoimmune disease were significantly more
likely by Chi-square to receive systemic-steroids (p<0.005) or to receive noncorticosteroid IMT (p<0.005). They were significantly more likely than those without
systemic disease to receive antimetabolites, and there was a significant association with
methotrexate, azathioprine, 6-mercaptopurine, or leflunomide. There was no statistically
significant association between the presence of a systemic autoimmune disease and
mycophenolate use. Biologics as a class were significantly more likely to be used in
patients with systemic autoimmune diseases. Patients with systemic autoimmune diseases
were significantly more likely to receive adalimumab, infliximab, rituximab, mesalamine,
sulfasalazine, or IVIG. Many of these agents were primarily used to treat the underlying
systemic condition.
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Patients
Treatments

n

Subtype
%

Diffuse

Etiology
Nodular

Necrotizing

Posterior

Idiopathic

Systemic

Infectious

Posttraumatic

Topical Agents
NSAIDs

9

3.5

9

0

0

0

7

2

0

1

Corticosteroids

115

44.9

101

7

4

3

60

43

3

9

Methotrexate

1

0.4

1

0

0

0

1

0

0

0

Systemic NSAIDs

87

34

81

4

0

2

60*

21

1

4

Sub-Tenon’s

11

2.4

7

3*

0

1

6

4

1

0

87

34

74

3

5*

5

37

47*

2

1

triamcinolone
acetonide

Immunosuppressive
Agents
Systemic
Corticosteroids
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Hydroxychloroquine

13

5.1

11

1

1

0

2

11*

0

0

Antimetabolites

82

32

72

5

3

2

28

52*

3

1

Methotrexate

44

17.2

40

1

2

1

15

28*

2

0

Mycophenolate

17

6.8

14

2

0

1

10

7

0

0

Leflunomide

5

2

4

0

1*

0

0

5*

1

1

Azathioprine

12

4.7

10

2

0

0

3

8*

0

0

6-mercaptopurine

4

1.6

4

0

0

0

0

4*

0

0

Biologics

37

14.4

30

5

2

1

6

31*

0

0

TNF-⍺ inhibitors

23

9.1

20

2

1

0

6

17*

0

0

Adalimumab

13

5.1

11

1

1

0

5

8*

0

0

Infliximab

5

2

4

1

0

0

0

5*

0

0

Etanercept

4

1.6

4

0

0

0

1

3

0

0

Certolizumab

1

0.4

1

0

0

0

0

1

0

0

Rituximab

6

2.4

5

1

0

0

0

6*

0

0

Tocilizumab

1

0.4

1

0

0

0

0

1

0

0

Tofacitinib

1

0.4

1

0

0

0

0

1

0

0

Vedolizumab

1

0.4

0

0

0

1

0

1

0

0

Abatacept

1

0.4

0

1

0

0

0

1

0

0
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Anakinra

1

0.4

1

0

0

0

0

1

0

0

IVIG

3

1.2

2

1

0

0

0

3*

0

0

Calcineurin

2

0.8

1

0

0

0

0

1

0

0

Cyclosporine

1

0.4

1

0

0

0

0

1

0

0

Tacrolimus

1

0.4

0

0

0

1

1

0

0

0

Alkylating agents

1

0.4

1

0

0

0

0

1

0

0

Cyclophosphamide

1

0.4

1

0

0

0

0

1

0

0

5-aminosalicylates

11

4.4

9

1

1

0

6

5

0

0

Mesalamine

6

2.4

6

0

0

0

1

5*

0

0

Sulfasalazine

5

2

3

1

1*

0

0

5*

0

0

Inhibitors

Table 9 Treatments used for the management of scleritis and underlying, systemic conditions, *p<0.05 when compared to
pooled other groups.
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Initial Treatments and Treatment Escalation
189 patients were given acute treatment to manage their inflammation. The most
common first-line treatment was topical steroids, which 76 (29.7%) received as their
first-line therapy, followed by systemic NSAIDs which were first-line for 77 patients
(30.1%), and systemic steroids which was used as the first line therapy in 64 patients
(25%).
Treatment escalation was defined as the addition of a second agent to control
inflammation. Since non-corticosteroid IMTs are more commonly used as steroid-sparing
agents rather for acute control of inflammation, they were not considered “treatment
escalation” for this analysis. People who had no follow up were also not included. Those
who received any topical agent (steroids or NSAIDs) as first-line therapy were
significantly more likely to need treatment escalation than those who received systemic
therapies (50% compared to 33.3%, p<0.05). Those who received topical steroids were
also more likely to require escalation than those on other therapies (49.2% compared to
34.4%), but the difference was not significant (p<0.1). There was no difference in the
need for escalation between systemic NSAIDs and corticosteroids.
Treatment Results
Resolution
45.6% of patients resolved within 3 months (47 of the 103 patients that were
followed for at least 3 months), 57.6% resolved within 6 months (53 of the 92 patients
that had at least 6 months of follow up), and 76.8% resolved within 12 months (62 of the
82 patients followed for 12 months)(Table 10). Mean resolution time was 138.55 +/21.55 days. Median resolution time was 67.5 days.
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Chi-square analysis was used to assess for associations with resolution at each
time point. Factors positively associated with resolution at the 3-month time point were
NSAIDs (p<0.01), lupus erythematosus (p<0.05), and 5-aminosalicylic acid use
resolution (p<0.1). Factors negatively associated with resolution at the 3-month time
point were bilateral scleritis (p<0.05) and mycophenolate (p<0.1).
Factors positively associated with resolution at the 6-month time point were
NSAIDs (p<0.01), lupus erythematosus (p<0.01), and Hispanic race (p<0.05). Factors
negatively associated with resolution at the 6-month time point were bilateral scleritis
(p<0.05), granulomatosis with polyangiitis (p<0.1), psoriasis (p<0.1), and rituximab
(p<0.1).
Factors positively associated with resolution at the 12-month time point were
NSAIDs (p<0.01), and Hispanic race (p<0.1). Factors negatively associated with
resolution at the 12-month time point were bilateral scleritis (p<0.05), granulomatosis
with polyangiitis (p<0.05). A student t-test demonstrated a negative association between
resolution at the 12-month time point and younger age (p<0.1, mean difference -7.749,
90% CI [-14.235, -1.263]). No other treatments, demographic factors, or comorbidities
were significantly associated with resolution.
Steroid Sparing Resolution
35.9% of patients achieved steroid sparing resolution within 3 months (37 of the
103 patients that were followed for at least 3 months), 48.9% within 6 months (45 of the
92 patients that had at least 6 months of follow up), and 69.5% within 12 months (57 of
the 82 followed for 12 months (Table 11). The mean time to steroid sparing resolution
was 210.93 days +/- 33.22. Median time to steroid sparing resolution was 78.5 days.
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Chi-square analysis was used to assess for associations with steroid sparing
resolution at each time point. At the 3-month time point the treatments positively
associated with steroid sparing resolution were NSAIDs (p<0.005), 5-aminosalcylic acid
(p<0.05), and sulfasalazine (p<0.05). The treatments negatively associated with steroid
sparing resolution were antimetabolites (p<0.05) and mycophenolate use (p<0.05).
Steroid sparing resolution was also positively associated with ulcerative colitis (p<0.1)
and negatively associated with chronic kidney disease (p<0.05) at the 3-month time point.
At the 6-month time point, the treatments positively associated with steroid
sparing resolution were NSAIDs (p<0.005) and 5-aminosalcylic acid use (p<0.1). The
treatments negatively associated with steroid sparing resolution were antimetabolites
(p<0.05) and mycophenolate use (p<0.05).
At the 12-month time point, the treatments positively associated with steroid
sparing resolution were antimetabolites (p<0.05) and NSAIDs (p<0.05). The only
treatment negatively associated with steroid sparing resolution was mycophenolate
(p<0.05). Steroid sparing resolution was also positively associated with Hispanic race
(p<0.1) and negatively associated with granulomatosis with polyangiitis (p<0.05) at the
12-month time point. A student t-test demonstrated a negative association between
steroid sparing resolution at the 12-month time point and younger age (p<0.1, mean
difference -6.481, 90% CI [-12.450, -0.512]). No other treatments, demographic factors,
or comorbidities were significantly associated with steroid sparing resolution.
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Time

Overall

period

Resolution

% Resolution by subtype

% Resolution by etiology

Diffuse anterior

Nodular

Necrotizing

Posterior

Idiopathic

Systemic

Infectious

Traumatic/Surgical

3 months

45.6%

48.3

33.3

50

25

43.9

48.7

40

40

6 months

57.6%

59

40

50

57.1

54

62.9

60

40

12 months

76.8%

77.1

50

50

100

75.5

78.8

100

60

Table 10 Resolution at 3-, 6-, and 12-month time points by scleritis subtype and etiology.

Time

Steroid

period

Sparing

% Resolution by subtype

% Resolution by etiology

Resolution
Diffuse anterior

Nodular

Necrotizing

Posterior

Idiopathic

Systemic

Infectious

Traumatic/Surgical

3 months

35.9%

36.9

16.7

50

25

35.1

35.9

40

40

6 months

48.9%

44.3

40

50

42.9

48.0

48.6

60

40

12 months

69.5%

63.2

50

50

80

67.4

69.7

100

60

Table 11 Resolution at 3-, 6-, and 12-month time points by scleritis subtype and etiology.
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Recurrence
Of the patients who had a resolution of their initial scleritis episode, two patients
(0.8%) had a recurrence of symptoms within 6 months and nine patients (3.5%) of
patients had a second episode within a year. Those who received systemic steroids were
less likely than those who did not (p<0.1) to have a second episode within a year. No
other treatments, demographic factors, or comorbidities were significantly associated
with resolution.
Complications
12 patients (4.7%) had one or more complications attributed to scleritis or its
treatments. This included elevated intraocular pressures in eight patients (3.2%), four
patients (1.6%) with retinal detachment, one patient (0.4%) with choroidal effusion, and
one patient (0.4%) with corneal scarring.
Two of the patients that developed elevated intraocular pressures had idiopathic
disease, one had infectious scleritis, and four had a systemic autoimmune disease. This
included two with Crohn’s disease, one with psoriasis, and one with mixed connective
tissue disorder.
Among those that had a retinal detachment, one had posterior scleritis, one had
nodular anterior scleritis, and two had diffuse anterior scleritis. Two had comorbid
rheumatoid arthritis and two had idiopathic disease. One patient went blind in the
effected eye secondary to the retinal detachment and another developed a choroidal
effusion.
One patient developed corneal scarring secondary to scarring from necrotizing
scleritis and required a corneal transplant.
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Multivariate Analysis
Binary Logistic Regression
Binary logistic regression was performed using resolution at 1 month, 3 months,
and 6 months, as well as steroid sparing resolution at 3 months and 6 months, as binary
end points. Univariate regression, as well as other univariate analysis such as Chi-square,
was used to identify variables that would be used in the multivariate model. There were
no significant associations with scleritis subtype or etiology in univariate analysis. To
identify factors specifically related to resolution of anterior non-infectious scleritis,
infectious and posterior scleritis were removed from the sample for the subsequent
multivariate analysis. Multivariate regression was repeated after limiting the sample to
only those with a diagnosis confirmed seen an ophthalmologist.
The 1-month resolution time point was used to identify the factors related to the
shortest and, presumably, mildest cases. The variables in the final model included age,
race, and gender, and had a Nagelkerke R2 of 0.207 and correct classification of 84%.
The only significant factor was Hispanic race (relative to Caucasian, p<0.005, OR
14.871, 95% CI [3.461,63.902]). When limiting the sample to only seen by an
ophthalmologist, systemic NSAIDs were significant at the 90% confidence level (p<0.1,
OR 3.337, 90% CI [1.101, 10.120]), and the R2 is 0.357 and the correct classification is
81.8%.
The final model for the 3-month resolution time point included age, gender,
NSAID use, and biologic use. The model had a Nagelkerke R2 of 0.272 and correct
classification of 72.3%. Systemic NSAIDs were significant at the 95% confidence level
(p<0.05, OR 5.068, 95% CI [1.791, 14.339]). At the 90% confidence level Hispanic race
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(p<0.1, OR 5.859, 90% CI [1.254, 27.376]) and biologic use (p<0.1, OR 3.864, 90% CI
[1.182, 12.672]) were significant. When limiting the sample to only those seen by an
ophthalmologist, systemic biologic use loses significance.
The final model using the resolution within 6 months endpoint included age,
gender, sex, systemic NSAIDs, and presence of systemic autoimmune disease. It had a
Nagelkerke R2 of 0.429 and a correct classification of 80%. The significant variables at
the 95% confidence level were systemic NSAID use (p<0.005, OR 1.747, 95% CI [2.548,
53.406] and systemic autoimmune disease (p<0.05, OR 4.525, 95% CI [1.057,19.357]).
Female gender was significant at the 90% confidence level (p<0.1, OR 0.288, 90% CI
[0.087, .958]). When limiting the sample to only seen by an ophthalmologist, systemic
autoimmunity became significant only at the 90% confidence level (p<0.1, OR 3.042,
90% CI [1.0004, 9.218]).
When using steroid sparing resolution at 3 months as the endpoint, the final model
included age, race, gender, systemic NSAID use, and being on methotrexate when the
episode started (i.e. on methotrexate at baseline). The model had a Nagelkerke R2 of
0.311 and a correct classification of 72.9%. The significant variables were systemic
NSAID use (p<0.005), OR 6.593, 95% CI [1.949,22.303]) and being on methotrexate
when the episode started (p<0.05, OR 5.983, 95% CI [1.197,29.460]). Methotrexate
started at later dates was not associated with steroid sparing resolution within 3 months.
When limiting the sample to only seen by an ophthalmologist, methotrexate becomes
significant only at the 90% confidence level (p<0.1, OR 3.368, 90% CI [1.0171, 10.588]).
When using steroid sparing resolution at 6 months as the endpoint, the final model
included race, gender, diagnosis age, systemic NSAID use, and being on methotrexate
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when the episode started. The model had a Nagelkerke R2 of 0.308 and a classification
69.9%. The only significant value at the 95% confidence level was NSAID use
(p<0.005), OR 8.089, 95% [2.379,27.500]). At the 90% confidence level being on
methotrexate when the episode started (p<0.1, OR 4.211, 90% CI [1.210,14.660]) and
Hispanic race (p=0.1, OR 5.518, 90% CI [1.002,30.382]) were significant. When limiting
the sample to only seen by an ophthalmologist, Hispanic race and methotrexate lose
significance.
Cox Proportionate Hazards Model
All comorbidities, demographic factors, and treatments that were considered to
have a potential effect on the course of a scleritis episode were individually inputted in a
Cox proportionate hazards model. Overall resolution and steroid sparing resolution were
used as separate endpoints. Demographic factors included age at time of diagnosis, sex,
race, and smoking status. Overall autoimmune status was assessed as well as specific
autoimmune diseases if they had more than five patients. These included rheumatoid
arthritis, granulomatosis with polyangiitis, lupus, psoriasis, Hashimoto’s thyroiditis,
Sjogren’s syndrome. Nonautoimmune comorbidities assessed included diabetes,
hypertension, hyperlipidemia, chronic kidney disease, cirrhosis, cancer, and chronic heart
failure, as well as the Charlson comorbidity index score. Treatments assessed included
systemic NSAID use, topical NSAIDs, systemic steroids, topical steroids, sub-Tenon’s
triamcinolone acetonide, methotrexate, mycophenolate, leflunomide, azathioprine,
rituximab, adalimumab, infliximab, etanercept, sulfasalazine, mesalamine, and
hydroxychloroquine as well as aggregated variables such as all patients on TNF-⍺
inhibitors, on antimetabolite agents, on biologics, on 5-aminosalicylic acid agents
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(sulfasalazine or mesalamine) or on any IMT. Combination effects were also assessed.
There were no significant associations with scleritis subtype or etiology in univariate
analysis. To identify factors specifically related to resolution of anterior non-infectious
scleritis, infectious and posterior scleritis were removed from the sample for the
subsequent multivariate analysis. Multivariate regression was repeated after limiting the
sample to only those with a diagnosis confirmed seen an ophthalmologist.
When modelling time to overall resolution, the significant factors at the 95%
confidence level in univariate Cox analysis were lupus (p<0.01, OR 4.317 when
compared to nonautoimmune patients), NSAID use (p<0.005, OR 2.249), Hispanic race
(p<0.05, OR 2.216). The individually significant agents at the 90% confidence level
included 5-aminosalicylic acid use (clustered mesalamine and sulfasalazine
patients)(p<0.1, OR 3.075), sulfasalazine (p<0.1, OR 3.633), Hashimoto’s thyroiditis
(p<0.1, OR 6.286), biologic use (p<0.1, OR 1.859), methotrexate at onset (p<0.1, OR
1.932), and granulomatosis with polyangiitis (p<0.1). A multivariate Cox regression
model was made starting with general demographic characteristics (age, diagnosis, sex)
and adding covariates one at a time. Variables that remained significant were kept,
variables that were not significant were removed. This was done first with all patients,
then with only patients with a diagnosis confirmed by an ophthalmologist. No
immunomodulatory agents were significant on initial analysis, but when restricting
analysis to only agents started early (within first 3 months of episode), TNF-⍺ agents and
methotrexate were significant at the 90% confidence level.
In the multivariate model with all patients the following factors were significant at
the 95% confidence level: topical Steroids (p<0.05, OR 1.979)(Figure 4), granulomatosis

63
with polyangiitis (p<0.05; OR 0.04), NSAID use (p<0.005, OR 2.779), lupus (p<0.05;
OR 23.976), TNF-⍺ inhibitor use (p<0.05, OR 2.327, 95% CI [1.101, 3.229]), biologic
started within 3 months (p<0.05, OR 2.321, 95% CI [1.111, 4.848], and bilateral scleritis
(p<0.05, OR 0.389). At the 90% confidence level the significant values were Hispanic
race (when compared to a Caucasian referent group) (p<0.1, OR 2.304, 90% CI [1.117,
4.750]), topical steroid use (p<0.1, OR 1.907 , 90% CI [1.062, 3.424])(Figure 7), and
methotrexate use (p<0.1, OR 1.805, 90% CI [1.050, 3.103]). When looking at only
patients with a diagnosis confirmed by an ophthalmologist, topical steroid and
methotrexate use lost significance. The significant factors in the smaller sample at the
95% confidence level were NSAID use (p<0.05, OR 2.145, 95% CI
[1.200,3.832])(Figure 5), Hispanic race (when compared to a Caucasian referent group)
(p<0.05, OR 2.664, 95% CI [1.036, 6.851])(Figure 6), lupus (p<0.005, OR 6.175, 95% CI
[1.774,21.489])(Figure 7), and bilateral scleritis (p<0.05, OR 0.437 , 95% CI [0.196,
0.972])(Figure 8). At the 90% confidence level TNF-⍺ inhibitor use was significant
(p<0.1, OR 2.210, 90% CI [1.100, 4.440]) (Figure 9). The final model included age, race,
gender, lupus, NSAID use, TNF-⍺ inhibitor use, and bilateral scleritis. The final model
was significant (p<0.05) using the Omnibus test of model coefficients. Survival functions
were plotted against 1-Survival on the y-axis to demonstrate the increasing proportion of
patients achieving resolution of inflammation over time.
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Figure 4 Resolution of scleritis with topical steroids; survival function plotting time
against the proportion of patients who achieved resolution of inflammation (1-Survival);
blue=did not receive topical steroids, red=received topical steroids.
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Figure 5 Resolution of scleritis with systemic NSAIDs; survival function plotting
time against the proportion of patients who achieved resolution of inflammation (1Survival); blue=did not receive systemic NSAIDs, red=received systemic NSAIDs;
p<0.05 when comparing those that received NSAIDs to those that did not.
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Figure 6 Race and resolution of scleritis; survival function plotting time against the
proportion of patients who achieved resolution of inflammation (1-Survival);
blue=Caucasian, red=African American, green=Asian, yellow=Hispanic, orange=other;
p<0.05 when comparing Hispanics to other groups.
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Figure 7 Resolution of scleritis in patients with lupus erythematosus; survival function
plotting time against the proportion of patients who achieved resolution of inflammation
(1-Survival); p<0.05 when comparing patients with lupus erythematosus to those who
have no autoimmune diseases and to those with no autoimmune diseases.
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Figure 8 Laterality of scleritis resolution survival function plotting time against the
proportion of patients who achieved resolution of inflammation (1-Survival);
blue=unilateral scleritis, red=bilateral scleritis; p<0.05.
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Figure 9 Resolution of scleritis with TNF-⍺ inhibitor use; survival function plotting time
against the proportion of patients who achieved resolution of inflammation (1-Survival);
blue=did not receive TNF-⍺ inhibitors, red=received systemic TNF-⍺ inhibitors; p<0.05.
When modelling time to steroid sparing resolution versus time, the following
variables were significant in univariate regression at the 95% confidence level: 5aminosalicylic acid drugs (p<0.05, OR 3.921), biologic therapy (when compared to
antimetabolite therapy) (p<0.05, OR 2.25), and etanercept (p<0.05, OR 9.434),
Hashimoto’s thyroiditis (p<0.05, OR 8.315), lupus (p<0.005, OR 3.066). At the 90%
confidence level TNF-⍺ inhibitors were significant (when compared to other IMTs)
(p<0.1, OR 0.088). Patients on biologics do better than those who did not receive either
class (p<0.1, OR 2.215, 90% CI [1.055, 4.650], as do those on both antimetabolites and
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biologics (p<0.05, OR 3.688, 95% CI [1.253,10.737)]). Patients on antimetabolites alone
did not do better than those not on either class.
Again, a multivariate Cox regression model was made starting with general
demographic characteristics (age, diagnosis, sex) and adding covariates one at a time.
The variables biologic treatment, TNF-⍺ inhibitors, and etanercept were not put into the
model at the same time, since they encompass one another, so three versions of the model
were made with one in each one. Significant variables did not change when looking at
only patients seen by an ophthalmologist. After limiting the patient sample, the
significant factors were lupus (p<0.05), OR 5.251, 95% CI [1.478,18.659])(Figure 9),
biologic therapy (when compared against antimetabolite p<0.01, OR 2.506, 95% CI
[1.406,7.634] (Figure 10), TNF-⍺ inhibitors (p<0.05, OR 3.346, 95% [1.277,8.763])
(Figure 11), etanercept (p<0.05, OR 10.686 95% CI [1.180,96.754])(Figure 12), and
NSAIDs (p<0.005), OR 2.558, 95% CI [1.383,4.729])(Figure 13).
Though those on antimetabolites appear to do worse than those who did not
receive either class of treatment (Figure 10), when looking at only those who received
treatment beginning in the first 3 months those two lines converge, and biologic use
remains significant (Figure 14). Similarly, when looking at only those who received
TNF-⍺ inhibitors within 3 months, the lines for other IMTs and no IMTs converge
(Figure 15). This indicates a possible lead-time bias that results in those on
antimetabolites and other IMTs appearing to do worse. For this reason, IMTs were only
included in the model if they were started within 3 months.
5-aminosalicylic acid drugs were only significant at the 95% in the version of the
model with etanercept (p<0.05, OR 6.157, 95% CI [1.198,31.633]) (Figure 16). When
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etanercept was replaced in the model with biologic therapy or TNF-⍺ inhibitors, it
became significant only at the 90% confidence level (p<0.1, OR 3.743, 90% CI
[1.098,12.755] in the version of the model with biologic therapy and p<0.1, OR 3.820,
90% CI [1.107, 13.184] with TNF-⍺ in the model). African American race (when
compared to a Caucasian referent group) was significant at 95% only in the version of the
model with Biologic therapy (p<0.05, OR 0.467,95% CI [0.224,0.973]. Though Hispanic
race was associated with better outcome in binary logistic regression, here it was not
when Caucasian race was used as the reference. When each race was compared to pooled
other races, Caucasian and Hispanic races were associated with significant effects
(p<0.05, OR 2.242, 95% CI [1.076,4.668] and p<0.05, OR 3.198, 95% CI[1.022, 10.005],
respectively)(Figure 17). Age was significant at the 90% confidence level in the models
with biologics and TNF-⍺ inhibitors (p<0.1, OR 1.024, 90% CI [1.003 1.045] and
p=0.068, OR 1.025, 90% [1.002, 1.049], respectively. Lupus and systemic NSAIDs were
significant at the 95% confidence level in all versions of the model. All versions of the
model were significant at p<0.005 using the Omnibus test of model coefficients. Given
that the biologics variable had the greatest N, and etanercept was a very small group (4
patients), the biologics version was considered the final model. Survival functions were
plotted against 1-Survival on the y-axis to demonstrate the increasing proportion of
patients achieving resolution of inflammation over time.
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Figure 9 Time to steroid sparing resolution of scleritis for patients with lupus
erythematous; survival function plotting time against the proportion of patients who
achieved steroid-sparing resolution of inflammation (1-Survival); p<0.05 when
comparing patients with lupus erythematosus to those who have no autoimmune diseases
and to those with no autoimmune diseases
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Figure 10 Time to resolution for scleritis patients on biologics, antimetabolites, or
neither; survival function plotting time against the proportion of patients who achieved
steroid-sparing resolution of inflammation (1-Survival); blue=patient did not receive
antimetabolites or biologic agents, red=patient received an antimetabolite; green=patient
received a biologic agent.

74

Figure 11 Time to resolution of scleritis for patients on TNF-⍺ inhibitors; survival
function plotting time against the proportion of patients who achieved steroid-sparing
resolution of inflammation (1-Survival); blue=patient did not receive antimetabolites or
biologic agents, red=patient received an antimetabolite.
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Figure 12 Time to resolution of scleritis for patients on etanercept; survival function
plotting time against the proportion of patients who achieved steroid-sparing resolution of
inflammation (1-Survival); blue=did not receive etanercept, red=received etanercept;
p<0.05 when comparing patients who received etanercept to those who did not.
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Figure 13 Time to resolution of scleritis for patients on NSAIDs; survival function
plotting time against the proportion of patients who achieved steroid-sparing resolution of
inflammation (1-Survival); blue=did not receive systemic NSAIDs, red=received
systemic NSAIDs; p<0.05 when comparing those that received NSAIDs to those that did
not.
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Figure 14 Time to resolution of scleritis for patients on biologics, antimetabolites, or
neither if initiated within 3 months of symptom onset; survival function plotting time
against the proportion of patients who achieved steroid-sparing resolution of
inflammation (1-Survival); blue=patient did not receive antimetabolites or biologic
agents, red=patient received an antimetabolite; green=patient received a biologic agent;
p<0.05 when comparing patients that received a biologic to other groups.
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Figure 15 Time to resolution of scleritis for patients on TNF-⍺ inhibitors if initiated
within 3 months of symptom onset; survival function plotting time against the proportion
of patients who achieved steroid-sparing resolution of inflammation (1-Survival);
blue=did not receive an IMT, red=received systemic TNF-⍺ inhibitors, green=received
another IMT; p<0.05 when comparing patients that received a TNF-⍺ inhibitors to other
groups.
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Figure 16 5-aminosalicylate (ASA) treatment and steroid sparing resolution; survival
function plotting time against the proportion of patients who achieved steroid-sparing
resolution of inflammation (1-Survival); blue=did not receive a 5-aminosalicylate
treatment, red=received a 5-aminosalicylate treatment.
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Figure 17 Race and steroid sparing resolution of scleritis; survival function plotting time
against the proportion of patients who achieved steroid-sparing resolution of
inflammation (1-Survival); blue=Caucasian, red=African American, green=Asian,
yellow=Hispanic, orange=other; p<0.05 when comparing Hispanics to other groups.
Discussion and Conclusion
Scleritis is an inflammatory disease with a number of etiologies. Most cases are
idiopathic, however 20-50% of cases may be associated with a systemic autoimmune
disease. (3-6). A smaller percentage have infectious etiologies, previously reported to be
8% of cases, with herpes simplex virus being the most common infectious etiology (10).
The distribution of etiologies of scleritis in our sample was consistent with previous
reports (3, 10, 11).
It is believed that scleritis has an autoimmune etiology (93). The high rate of
systemic autoimmune comorbidities and the female preponderance of the disease are
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pointed to as evidence for this. In our sample, patients with idiopathic scleritis and those
with scleritis associated with a systemic autoimmune condition were predominately
female. Notably, patients with infectious scleritis were also predominately female. Other
autoimmune diseases have been reported to be triggered by infectious agents, and it is
possible that scleritis can similarly be triggered in susceptible patients. A number of
mechanisms have been proposed for female susceptibility to autoimmune disease,
including gender differences in immune reactivity, hormones, epigenetics, and
environmental exposures such as infectious and chemical agents (94).
Similar to previous studies, a high percentage of patients (35.2%) in our sample
had a systemic autoimmune disease (2-3, 6-8), As with previous reports rheumatoid
arthritis was the most common autoimmune comorbidity, though we did have a higher
percentage of patients with inflammatory bowel disease, psoriasis, and lupus
erythematosus than previous studies (1-2, 7-9). The high proportion of patients with
asthma is also consistent with an autoimmune etiology of scleritis. The proportion of
patients with asthma in our sample was significantly higher than the population
prevalence of asthma reported by the CDC, even when accounting for gender (92).
Though not classically considered to be an autoimmune disease, asthma has an immunemediated mechanism and has been associated with other autoimmune diseases such as
type 1 diabetes mellitus in population studies (95-96). Though not previously reported,
scleritis seems to also be associated with a diagnosis of asthma, and future studies may
wish to assess if patients with asthma or at a greater risk of developing scleritis.
Also notable was the high prevalence of mental health disorders, particularly
generalized anxiety and major depression, in our sample. The prevalence in our sample
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was significantly higher than population averages as reported by the National Institutes of
Mental Health (91). Multiple studies have reported associations between autoimmune
diseases and psychological stress (97-100). Uveitis has been associated with
psychological stress and major depression (101-102). There is conflicting literature on the
etiology of this, with some proposing that immune dysfunction has neuropsychological
effects or, inversely, that the proinflammatory effects of chronic stress are predisposing
factors for autoimmunity (97). In uveitis it has been proposed that impairment in the
ability to perform, pain, and fear of losing work secondary to their disease contributes to
distress, depressive moods, and worsened overall health (101). It is possible that a similar
process happens in patients with scleritis. To the authors’ knowledge there have been no
studies on the association between scleritis and mental health to date. However, there are
studies that demonstrate an association between chronic corticosteroid use and mental
health disorders, particularly depressive disorders (103-104). This has not been
previously described in scleritis patients but may have important ramifications for
treatment compliance and patient quality of life. It may be beneficial to connect patients
with resources to help them cope with the psychosocial stresses of their disease, such as
psychotherapy or support groups.
A number of demographic factors and comorbidities have been previously
reported to be associated with the resolution of non-infectious anterior scleritis (8, 19-22).
Though not previously reported, there were significant racial differences in the course of
scleritis in the patients in our sample. Hispanic patients were significantly more likely
than Caucasian patients to have resolution of their scleritis within one month in a
multivariate binary regression model. Our survival curves demonstrate that Hispanic
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patients achieve resolution of symptoms and steroid sparing resolution faster than other
ethnic groups. In our Cox proportionate hazards model, being African American was
negatively associated with achieving steroid sparing resolution when compared to
Caucasian patients. It is unclear why there may be racial differences in the length of an
episode of scleritis. Studies on other autoimmune diseases such as systemic lupus
erythematosus, rheumatoid arthritis, autoimmune hepatitis, and primary biliary cirrhosis
have found racial differences in prevalence and severity of disease (105-109). Several
theories have been proposed for this including genetic differences, environmental factors,
and race or socioeconomic-based healthcare disparities (106-107, 110-113). In our
sample Hispanic patients were younger than Caucasian patients at the time of diagnosis,
though the difference was not statistically significant. African American patients were
more likely than others to have concurrent uveitis, though the difference was not
significant. This may indicate a propensity towards a greater degree of ocular
inflammation. There were no racial differences in treatment utilization, however we were
unable to assess differences in time to presentation, which may have been a contributing
factor.
Bilateral scleritis was inversely associated with resolution of scleritis in our Cox
proportional hazards model (p<0.05, OR 0.437, 95% CI [0.196, 0.972]). Bilateral scleritis
has been associated with systemic autoimmune conditions including granulomatosis with
polyangiitis and relapsing polychondritis (21, 114). In our sample, bilateral scleritis was
significantly associated with having more than one systemic autoimmune disease by
univariate analysis, which may reflect the severity of autoimmunity. It has previously
been documented that patients with systemic autoimmune comorbidities require more
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aggressive treatment to manage scleritis (20). The difficulty in controlling bilateral
disease may be reflective of this.
Lupus erythematosus was also significantly associated with resolution and
steroid-sparing resolution. Typically, systemic autoimmune disease is associated with
scleritis that is more difficult to control (20), however in our sample there did not appear
to be a significant difference between those with systemic autoimmunity and those with
systemic autoimmune conditions other than lupus. Nine patients in our sample had lupus,
including one with discoid lupus and eight with systemic lupus. It is unclear why these
patients tended to have faster resolution times when compared to those with no systemic
autoimmunity and those with other systemic autoimmune conditions. Similar to the other
autoimmune diseases in our sample, the majority of them were female, and most of them
received systemic corticosteroids and non-corticosteroid IMTs. Four of them received
mycophenolate, one received methotrexate, one received azathioprine, and two received
rituximab. None of the individual treatments they received were overrepresented in lupus
patients when compared to patients with other autoimmune conditions. It may be that
patients with lupus-associated scleritis have more mild disease compared with other
scleritis patients.
Patients with scleritis received a number of different treatments, most commonly
topical steroids (44.9%), systemic NSAIDs (34%), and systemic steroids (34%). A noncorticosteroid IMT was required in 39.5% of patients to manage their scleritis. Similar to
other studies, patients with a systemic autoimmune disease required more aggressive
treatment and were likely to receive systemic steroids and non-corticosteroid IMTs (20).
Systemic NSAIDs were significantly associated with recovery (p<0.05, OR 2.145, 95%
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CI [1.200,3.832]). It is possible that those with more severe, long-lasting disease were
initially more aggressively treated and did not trial NSAIDs first. In that case the results
of the Cox model may have been skewed by the longest, most severe cases. The results of
the binary logistic regression confirm that systemic NSAIDs are positively associated
with resolution within 3 months. NSAIDs were more commonly used in younger patients,
likely due to contraindications or fear of side effects. Patients with contraindications such
as peptic ulcer disease or chronic kidney disease were more likely to be older. Age,
however, was not associated with time to resolution, so it is unlikely that it explains the
effect of systemic NSAIDs.
Biologic use was associated with achieving steroid sparing resolution when
compared to patients on antimetabolites. TNF-⍺ inhibitor use in particular was
significantly associated with achieving steroid sparing resolution when compared to
patients on other IMTs and to patients on no IMTs. The most common TNF-⍺ inhibitors
used were adalimumab and infliximab. Though etanercept demonstrated a positive
treatment effect, it is difficult to draw conclusions from this due to the limited number of
patients that received this treatment. Previous studies have demonstrated that etanercept
is not effective in the treatment of scleritis and other ocular inflammatory disease (71).
There was no significant difference between those who received no IMTs and those who
received an IMT that was not a TNF-⍺ inhibitor. Presumably, patients who required an
IMT to achieve steroid sparing resolution had more severe disease, so it may not be
accurate to compare those on IMTs to those not on IMTs without adjusting for disease
severity. In this study we were unable to measure disease severity. This may be useful to
assess in future studies. TNF-⍺ inhibitor use was also positively associated with
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resolution, though the outcome was only significant at the 90% confidence level. In order
to account for lead time bias, the analysis only included agents started within a fixed time
frame (three months). When repeating the analysis without making this adjustment, these
treatments are still significantly associated with achieving steroid sparing resolution,
though the survival curve for the treated patients demonstrate longer times to steroid
sparing resolution. To the authors’ knowledge this is the first study to compare the
different classes of IMTs in the treatment of scleritis.
Though there was only a small number of patients with necrotizing scleritis, there
were a number of interesting trends observed. For example, four of the five (80%) had a
systemic autoimmune association, and all three that had scleromalacia perforans had
rheumatoid arthritis. They were also more likely to require systemic steroids. On
univariate analysis necrotizing scleritis was significantly associated with vascular risk
factors such as diabetes mellitus and history of cocaine use, indicating a possible
vasculopathy etiology to necrotizing scleritis. They were more likely to be older and to
have a higher Charlson comorbidity index score. This may indicate that patients who are
overall less healthy are more likely to develop necrotizing scleritis. In contrast, patients
with diffuse anterior scleritis were significantly younger and had lower Charlson
comorbidity index score on average. To the authors’ knowledge, no other studies have
quantified the general health of patients with scleritis.
The majority of patients in our sample had an ophthalmologist involved in the
management of their scleritis, either as the sole provider or as a part of a multidisciplinary
team. A number of patients had their scleritis managed only by their primary care doctor,
rheumatologist, or were treated by an emergency room physician without follow up.
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Since in these cases the diagnosis was not confirmed by an ophthalmologist, it cannot be
known if these patients truly had scleritis or if they had another cause of “red eye” such
as episcleritis, conjunctivitis, or uveitis. For this reason, the main analysis was performed
once including all patients and again in patients whose diagnosis was confirmed by an
ophthalmologist. To be conservative, the final models were generated using the more
restricted sample. In most cases the significant variables remained the same, with a few
exceptions. In those cases, the loss of significance may have been due to a decrease in the
sample size, or because of differences in the patients seen by different specialties. Those
who received an ophthalmologic consultation could be those with more severe disease.
For example, in the Cox proportionate hazards model topical steroids lost significance
after restricting the sample to only those seen by an ophthalmologist. This may have been
because patients treated by a primary care doctor, rheumatologist, or emergency room
physician were milder cases more amenable to topical treatment. Alternatively, some of
those cases may have actually been of a milder condition, such as episcleritis, that was
misdiagnosed as scleritis.
Cases in which non-ophthalmologist providers are comfortable treating without
consulting ophthalmology may be milder cases. This can be seen by the types of patients
seen by each provider type in our sample. For example, all cases of necrotizing scleritis
and posterior scleritis had an ophthalmologist involved in their care, indicating that other
providers may not be comfortable treating these patients independently. Primary care
doctors were more likely to independently manage patients with idiopathic, anterior
disease, and they were also less likely to treat patients who required systemic
corticosteroids or IMTs. Patients with systemic autoimmune disease were more likely to
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be seen by rheumatology, ophthalmology, or a combination of the two. Given the high
prevalence of systemic autoimmune conditions in patients with scleritis, patients may
benefit from a multidisciplinary approach to therapy. This would allow for closer
monitoring of local and systemic disease and for prompt escalation of therapy when
needed. The prevalence vision-threatening complications and comorbid ophthalmic
diseases such as uveitis in patients with scleritis highlights the importance of close
monitoring in these patients. Though it is possible that patients not referred to
ophthalmology have milder disease, these patients may still need ophthalmologic
consultation.
There was a difference in treatment utilization depending on specialty type.
Patients who had an ophthalmologist involved in their care were overall more likely to
receive acute treatment than those not seen by ophthalmologists. Patients who had an
ophthalmologist involved in their care were more likely to receive systemic NSAIDs,
which previous reports have considered to be the preferred first line agent for scleritis
(12-13). Of those seen by an emergency medicine physician, 13% received only a single
dose of ketorolac in the emergency room and then were lost to follow up. This could
indicate a benefit to involving an ophthalmologist in the care of patients with scleritis.
The majority of those managed by rheumatology alone required systemic corticosteroids
or an IMT to manage their scleritis, and these more severe cases may also benefit from
the involvement of an ophthalmologist. To the authors’ knowledge no previous studies
have compared the treatments utilized for scleritis among different provider types.
There were some limitations to our study. We studied patients at a tertiary care
center, which may see more severe cases than those in the community. Though our study
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included more patients then many preceding studies, the sample size is still limited and
precludes extensive subgroup analyses. Additionally, severity of scleritis was not
documented in all charts so could not be included in the analysis. The retrospective
nature of our study also has its inherent limitations, particularly in deducing cause-effect
relationships. Our study did, however, find a number of associations that can be further
elucidated in future prospective studies.
In conclusion, scleritis is an inflammatory eye disease with a large number of
treatments. Patient characteristics including a lupus diagnosis and Hispanic race were
associated with resolution and steroid sparing resolution, as were treatments including
systemic NSAIDs and TNF-⍺ inhibitors. There were differences in medication utilization
among specialty types, and patients with scleritis may benefit from ophthalmologic
consultation. Future prospective studies will further elucidate the relationship between
these factors and patient outcomes.
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